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FOREWORD 
     Regulated cell death (RCD) is an essential phenomenon occurring inside every living organism 
from a single prokaryote to a complex human body. RCD is participating in a broad spectrum of 
important physiological and pathological processes. Removing the damaged, dysfunctional or 
infected cells is essential for embryogenesis and maintains the fragile balance/homeostasis in an 
adult organism. Disruption of this balance leads to a number of pathological states and diseases. 
Unsubstantiated cell death during brain or heart ischemia and in drugs/alcohol-damaged liver leads 
to impaired function of these organs and often ends with death of a patient. On the other hand 
attenuation of the cell death by viruses protects their host from premature cell death thus allowing 
viral replication to proceed. Additionally and importantly, regulated cell death serves as a natural 
barrier to tumour formation and cancer progression and became a target of many anti-cancer 
therapies. TRAIL ligand, a member of TNFα ligand family inducing extrinsic apoptosis, was 
showed to induce apoptosis in vitro and in vivo in various cancer cells while sparing the normal 
ones. Its ability to selectively kill tumour cells without systemic toxic side effects has raised initial 
expectations that regrettably led to disappointments in clinical trials. Recombinant TRAIL ligands 
or apoptosis-inducing TRAIL-receptor monoclonal antibodies did not manifest a satisfying 
outcome in clinical trials with no or minimal effect on suppression and elimination of various 
tumours. Though unsuccessful, the outcome from these trials led to the formulation of better and 
possibly patient-tailored therapeutic protocols, which include the use of novel sensitizers and the 
discovery and preparation of modified TRAIL-based agents, thus opening a new window of 
opportunity for its use in cancer therapy. Importantly, new discoveries concerning the possible 
involvement of non-canonical TRAIL signalling in cancer progression, invasion and metastasis 
raised new questions, which now need to be examined and answered. 
     In my thesis I was mainly focused on analysis of canonical and non-canonical TRAIL-induced 
signalling in human cells. In the Literature Review I summarized the recent knowledge about two 
main types of regulated cell death: canonical apoptosis and non-canonical necroptosis and 
involvement of TRAIL ligand in both of these processes. In addition I also examined other types 
of non-canonical TRAIL-induced signalling such as activation of NFκB, JNK and p38 kinase 
pathways. The following Result section in the Thesis is divided into three parts. The first one 
comprises the major piece of my Thesis work recently published in BBA Molecular Cell Research 
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with my first authorship. In this project I prepared a new set of TRAIL ligands and addressed 
TRAIL receptor (DR4 and DR5) selective canonical and non-canonical signalling. Searching for 
the new types of recombinant proteins and the possible differences in the signalling of the two 
receptors DR4 and DR5 in different cancer cell lines can lead to more specific patient customized 
treatment and better clinical outcome. The second part presents the data from the published article 
on TRAIL-induced signalling in human embryonic stem cells, a collaborative project between our 
and Ales Hampl (MU Brno) laboratory. In this study we examined a role of TRAIL ligand and 
extrinsic apoptosis in human embryonic stem cells (hESC) and human-induced pluripotent stem 
cells (hiPSC). The outcome of this study could be a useful material for further research and use in 
various biomedical applications from cell therapy to disease modelling or drug development. The 
final third part presents the data from yet unpublished work about Manumycin A and its 
mechanism of sensitizing colorectal cancer cells to not only TRAIL-induced apoptosis. Searching 
for the new sensitizers to overcome resistance to TRAIL-induced cell death is important part of 
cancer research. Finally, in the Discussion part, I compared our data with other published studies 
and discussed them especially in the context of cancer research. 
      
 
 
 
 
Zuzana Nahácka, Prague, 2019 
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ABSTRACT                                                                               
     TRAIL ligand can trigger apoptosis of permissive human cells via engagement of its two pro-
apoptotic receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5). Its ability to induce apoptosis 
independently on p53 status and to selectively kill cancer cells in vitro and in vivo made this ligand 
an attractive target in cancer research. However, acquired resistance of primary cancer cells, 
unsatisfactory outcome of clinical trials and recent studies arguing that TRAIL might under 
specific conditions promote cancer progression, opened new plethora of questions, which need to 
be addressed.  
     Though both receptors DR4 and DR5 are ubiquitously expressed, different types of tumours 
show preference for either of the receptors. The relative participation of DR4 and DR5 in TRAIL-
induced signalling is still largely unknown. To analyse TRAIL receptor-specific signalling, I 
prepared Strep-tagged, trimerised variants of recombinant human TRAIL ligands with high 
affinity for either DR4 or DR5 receptor. Using these receptor-specific ligands, I examined a 
contribution of individual pro-apoptotic receptors to TRAIL-induced signalling pathways. I found 
that in TRAIL resistant colorectal HT-29 cells but not in pancreatic PANC-1 cancer cells, DISC 
formation and initial caspase-8 processing proceeded comparably in both DR4- and DR5-activated 
receptor complexes. However, TRAIL-induced apoptosis proceeded in both cell lines 
predominantly via DR5 receptor. ShRNA-mediated downregulation of DR4 or DR5 receptors in 
HT-29 cells also pointed to a stronger contribution of DR5 in TRAIL-induced apoptotic signalling. 
In contrast to TRAIL-induced apoptosis, I did not observed significant differences in necroptotic 
signalling activated either by DR4- or DR5-specific ligands. Activation of auxiliary signalling 
pathways involving NF-κB and stress kinases p38 and JNK proceeded under apoptotic conditions 
mainly in a DR5-dependent manner, while these kinase pathways were during necroptosis 
similarly activated.  
     In addition to TRAIL receptor-specific signalling this Thesis introduces Manumycin A (Man 
A) as an effective sensitizer of TRAIL-induced apoptosis in colorectal cancer cell lines RKO and 
SW-620. I documented that treatment of RKO and SW-620 with Manumycin A in combination 
with TRAIL ligand or ABT-199/737 led to statistical increased apoptosis and co-treatment of these 
cells with Man A and TRAIL WT led to stronger activation of caspases -8/ -9 and caspase-3 as 
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well as increased processing of caspase-3 targets PARP and Bid proteins. Importantly I found out 
that this sensitizing effect is most probably related to the enhanced production of likely 
mitochondrial ROS in ManA-treated cells.  
     Additionally, data from the collaborative project on human embryonic stem cells (hESC) and 
human-induced pluripotent stem cells (hiPSC) showed that despite expression of both DR4 and 
DR5 receptors in these cells, they were naturally resistant to TRAIL-induced apoptosis. However, 
their pre-treatment with homoharringtonine led to decrease of expression of two anti-apoptotic 
proteins Mcl-1 and cFLIP and to their sensitization to TRAIL-induced apoptosis. Similarly 
shRNA-mediated downregulation of cFLIP led to their enhanced apoptotic response to TRAIL 
and thus cFLIP likely represents the important regulatory node in TRAIL-induced apoptosis of 
human pluripotent stem cells. 
     In summary, this study provided several new options how to overcome cellular resistance to 
TRAIL-triggered apoptosis and proposed answers to several questions raised in the field of 
TRAIL-induced signalling. It also provided first systematic insight into DR4-/DR5-specific 
signalling in colorectal and pancreatic cancer cells, where using a number of approaches 
documented that apoptotic and auxiliary but not necroptotic signalling in these cells largely relies 
on DR5 receptor. Moreover, I proposed secondary metabolite of Streptomyces Manumycin A as a 
novel potent sensitizer of TRAIL-induced apoptosis and I provided the first evidence that, 
irrespective of their origin, human stem cells express canonical components of the extrinsic 
apoptotic system and upon stress can activate death receptor-mediated apoptosis. 
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ABSTRAKT 
     TRAIL ligand spouští apoptózu interakcí se svými dvěma pro-apoptotickými receptory 
TRAIL-R1 (DR4) a TRAIL-R2 (DR5). Jeho schopnost indukovat apoptózu nezávisle na statusu 
p53 a selektivně zabíjet rakovinné buňky in vitro a in vivo zapříčinila, že tento ligand patřící do 
rodiny cytokinů TNF se jevil atraktivním cílem výzkumu terapie nádorových onemocnění. Avšak 
rezistence mnoha primárních nádorových buněk, neuspokojivý výsledek klinických testů a 
nedávné studie, které ukazují protichůdné výsledky a to konkrétně, že TRAIL může za 
specifických podmínek podporovat místo toho, aby inhiboval progresi nádorů, vyvolaly v oblasti 
výzkumu signalizace indukované ligandem TRAIL nové množství otázek, které je potřeba 
zodpovědet.  
     Ačkoliv jsou oba receptory DR4 a DR5 rovnoměrne exprimovány, různé typy nádorů vykazují 
preferenci pro jeden nebo druhý z receptorů. Relativní účast signalizace DR4 a DR5 indukované 
TRAIL ligandem je málo známá. Abychom analyzovali signalizaci ligandu TRAIL specifickou 
pro jednotlivé receptory, připravili jsme trimerizované varianty rekombinantního lidského ligandu 
TRAIL, značené pomocí Strep-tag, s vysokou afinitou pro receptory DR4 nebo DR5. Zjistila jsem, 
že narozdíl od pankreatických rakovinových buňek PANC-1 rezistentních k apoptóze indukované 
ligandem TRAIL, probíhá tvorba komplexu DISC a počáteční autoaktivace kaspázy-8 v 
rezistentních kolorektálních buňkách HT-29 srovnatelně jak v buňkách aktivovaných DR4, tak i 
DR5 ligandem. Apoptóza indukovaná ligandem TRAIL probíhala v obou buněčných liniích 
mnohem efektivněji prostřednictvím receptoru DR5. Potlačení exprese receptorů DR4 a DR5 
pomocí shRNA v buňkách HT-29 také ukázalo na významnější přínos receptoru DR5 v apoptóze 
indukované ligandem TRAIL. Na rozdíl od apoptotické buněčné smrti jsem nezaznamenala 
statisticky významné rozdíly v nekroptotické signalizaci, která byla srovnatelně aktivována jak 
ligandy specifickými pro DR4, tak i DR5 receptor. Aktivace dalších signálních drah, zahrnujících 
NF-κB a stresové kinázy p38 a JNK, probíhala za apoptotických podmínek hlavně DR5-
dependentním způsobem, zatímco tyto signalizační cesty byly v průběhu nekroptózy srovnatelně 
aktivovány. 
     V dizertační práci jsem dále také ukázala, že sekundární metabolit streptomycét Manumycin A 
je ve srovnání s příbuzným Manumycinem B nebo Asukamycinem účinným senzitizátorem 
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apoptózy indukované ligandem TRAIL v buněčných liniích RKO a SW-620 kolorektálního 
karcinomu. Dokázala jsem, že inkubace RKO a SW-620 s Manumycinem A v kombinaci s TRAIL 
ligandem nebo ABT199/737, vedla ke statisticky významnému zvýšení apoptózy. Také jsem 
ukázala, že společná inkubace Manumycinu A s ligandem TRAIL vedla k silnější aktivaci kaspáz 
-8 / -9 a kaspázy-3, stejně jako k zvýšenému šťepení  proteinů PARP a tBid. Důležité bylo zjištění, 
že tento ko-aktivační efekt je pravděpodobně způsoben produkcí ROS generovaných 
mitochondriemi.  
     Závěrem, údaje ze spolupráce s Vladimírem Vinarským a kol. ukazují, že lidské embryonální 
kmenové buňky (hESC) a lidské pluripotentní kmenové buňky (hiPSC) exprimují receptory DR4 
i DR5, ale jsou rezistentní vůči apoptóze indukované ligandem TRAIL. Souběžná inkubace s 
inhibitorem translace homoharringtoninem a ligandem TRAIL vedla k senzitizaci buňek k 
apoptóze indukované ligandem TRAIL a ke snížení exprese dvou antiapoptotických proteinů Mcl-
1 a cFLIP. Ukázala jsem, že potlačení exprese cFLIP pomocí shRNA vedla ke zvýšené citlivosti 
hESC, a že cFLIP pravděpodobně představuje důležitý regulační uzel ve vňejší dráze apoptózy 
indukované ligandem TRAIL v lidských pluripotentních kmenových buňkách. 
     Souhrnně vzato, představila jsem první systematický pohled na DR4-/DR5-specifickou 
signalizaci v kolorektálních a pankreatických rakovinných buňkách, kde jsem použitím několika 
přístupů prokázala, že pro-apoptotická, ale ne nekroptotická, receptor-specifická signalizace 
ligandu TRAIL může v kontrastu s posledními studiemi do značné míry probíhat prostřednictvím 
receptoru DR5. Také jsem ukázala, že Manumycin A je efektivním senzitizátorem apoptózy 
indukované ligandem TRAIL a poskytla jsem  první důkaz, že pluripotentní kmenové buňky, 
nezávisle na jejich původu, exprimují kanonické složky vnějšího apoptotického systému a vlivem 
stresových faktorů mohou aktivovat apoptózu zprostředkovanou receptory indukující buňečnou 
smrt. 
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LIST OF ABBREVIATIONS 
 
4 HB                                        four helical bundle domain 
ADAM10/17                           metallo-proteinase domain-containing protein 10/17 
AIF                                          apoptosis inducing factor 
APAF-1                                   apoptotic protease activating factor 1 
BH                                           Bcl-2 homology domain 
BIRC                                      baculovirus IAP repeat BIR containing domain 
BR                                           brace region 
CAD                                        caspase activated DNAse  
CAMK2D                               calcium/calmodulin dependent protein kinase type II subunit delta 
CARD                                     caspase activation and recruitment domain 
CB domain                             calmodulin-binding domain 
CRD                                        cysteine rich domain 
DD                                           death domain 
DED                                        death effector domain 
DISC                                       death inducing signalling complex 
DNA                                        deoxyribonucleic acid 
FADD                                     Fas associated death domain protein 
FLICE                                    Fas-associated death-domain-like interleukin-1beta-converting      
enzyme 
cFLIP                                     FLICE inhibitory protein  
IAP                                         inhibitor of apoptosis 
ID                                            intermediate domain 
IKK complex                         inhibitor κB of kinase complex 
KD                                          kinase domain 
MLKL                                    mixed lineage kinase domain-like protein 
MOMP                                   outer mitochondrial membrane permeabilization 
OMM                                     outer mitochondrial membrane 
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PAMPS                                  pathogen-associated molecular patterns  
PCD                                        programmed cell death 
PIP                                          phosphatidylinositol phosphate 
PKC                                       protein-kinase C 
PLAD                                     pre-ligand assembly domain 
PRR family                            pathogen recognition receptor family 
PS                                           phosphatidyl-serine 
RCD                                       regulated cell death 
RHIM                                    RIP homotypic interaction motif 
RING                                     C-terminal Ring zinc-finger, RING- Really Interesting New Gene 
RIPK1                                   receptor-interacting protein kinase 1 
RIPK3                                   receptor-interacting protein kinase-3  
RNA                                      ribonuclease acid 
tBid                                        truncated Bid 
TIR                                        Toll/interleukin receptor domain 
TNFα                                     tumour necrosis factor α 
TNFSF                                  TNF super-family 
TNFRSF                                TNF receptor super-family 
TRADD                                 TNF receptor-associated death domain protein 
TRAF2                                  TNF receptor-associated factor 2 
TRAIL                                  TNF-related apoptosis inducing ligand  
TRIF                                     TIR-domain containing adaptor-inducing IFN-beta 
ZBP1- Z-DNA                      binding protein 1 (DAI - DNA dependent activator) 
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1 LITERATURE REVIEW 
 
1.1 Programmed cell death 
     Programmed cell death (PCD) is referred as a process of genetically-regulated physiological 
cell death, a self-suicidal cell mechanism proceeding at specific time and place during the 
development of an organism, occurring predominantly during embryogenesis. The term 
programmed cell death was firstly used by Lockshin in 1963 to refer to cell death of intersegmental 
muscles of Bombyx Mori (Lockshin, 1963). Later Kerr, Wyllie and Currie proposed term apoptosis 
for the process of controlled cell deletion, which plays an opposite role to mitosis in the regulation 
of cell populations (Kerr et al., 1972). Currently among the regulated modes of cell death belong 
in addition to caspase-dependent apoptosis also other morphological distinct types of cell death 
such as regulated necrosis/necroptosis, autophagic cell death, pyroptosis, ferroptosis and others 
(Vanden Berghe et al., 2014; Galluzzi et al., 2018). 
1.1.1 Apoptosis 
     Apoptosis is physiological, genetically controlled and evolutionary conserved mode of cell 
death. It is a major mode of elimination of unnecessary or damaged cells in multicellular organisms 
(Green and Llambi 2015). This process is indispensable for the normal development of an 
organism, maintenance of homeostasis and proper functioning of the immune response. 
Dysregulated apoptosis can lead to developmental disorders, autoimmune and neurodegenerative 
diseases or tumorigenesis (Kerr et al., 1972; Baehrecke et al., 2002). Although there is a wide 
range of physiological and pathological conditions which trigger apoptosis, not all cells will 
necessarily die in response to the same stimulus. Apoptosis could be triggered by internal as well 
as external stimuli. Internal stimuli are mainly related to cellular stress, which can be induced by 
heat, radiation, nutrient deprivation, viral infection, hypoxia, misfolded proteins, damaged 
chromosomal DNA or increased calcium concentration. External stimuli cover mainly interaction 
of death ligands with their cognate receptors and dependance receptor triggered apoptosis. 
Apoptosis is accompanied by specific morphological and biochemical features, which are 
summarised in Table 1. In early phases occurs cell shrinkage, pyknosis, condensation and 
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fragmentation of chromatin in the nucleus, cytoplasm becomes more dense and organelles are 
tightly packed, cells become round and detached from the cell surface (Kerr et al., 1972; Grootjans 
et al., 2017). Cell shrinkage is accompanied by changes at the plasma membrane where transient 
blebbing and budding of the membrane results in the formation of apoptotic bodies - structures 
with intact plasma membrane, maintained organelle integrity with or without nuclear fragments. 
One of the well-known features of caspase-dependent apoptosis, exploited for its detection and 
quantification, is plasma membrane externalisation of phosphatidyl-serine (PS) by a flip-flop 
mechanism. Externalized PS serves as an eat-me signal for phagocytosis of apoptotic bodies by 
macrophages, parenchymal cells or neoplastic cells. Apoptosis is not accompanied with an 
inflammatory immune response as apoptotic cells do not release the cell content into surrounding 
area and are very rapidly phagocyted preferably by macrophages in a process called efferocytosis, 
preventing the secondary necrosis and production of pro-inflammatory cytokines (Savill et al., 
2000; Kurosaka et al., 2003). Besides typical morphological changes on the cellular level, 
apoptosis is also accompanied by distinct biochemical events. For most of the biochemical events 
are responsible specific cysteine proteases called caspases and specific DNAses. Caspases cleave 
a number of structural and functional proteins including the nuclear laminin and contribute to the 
disruption of the nuclear envelope and activation of Caspase Activated DNAse (CAD) that 
eventually can cleave chromosomal DNA into small pieces of 180 to 200 base pairs (Bortner et 
al., 1995; Enari et al., 1998).  
 
Morphological changes Biochemical/functional changes 
cell volume shrinkage activation of initiator and effector caspases 
cytoplasm condensation changes in the mitochondrial membrane potential 
nuclear envelope fragmentation cleavage of distinct structural and functional proteins 
nucleus fragmentation cleavage of chromosomal DNA 
formation of apoptotic bodies externalization of PS 
plasma membrane blebbing increased free calcium levels 
cell detachment secretion of find-me molecules  increased concentration of free calcium 
rapid phagocytosis    
Table 1: Morphological and biochemical changes occurring during apoptosis (Kerr et al., 
1972; Grootjans et al., 2017). 
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1.1.1.1 Caspases, the key molecules in apoptosis 
 
     The core of the apoptotic machinery is formed by caspases, enzymes of the family of cysteine-
dependent proteases, which cleave the substrate behind the aspartic acid. Caspases are expressed 
as an inactive zymogens that need to be activated by (auto)processing at certain time and place. 
Caspases were identified in all multicellular animal organisms and their relatives metacaspases 
and paracaspases were found in plants, funghi and even prokaryots (Boyce et al., 2004). Caspases 
as executioners of apoptosis were initially discovered in the nematode Caenorhabditis elegans, 
where caspase CED-3, which possesses a substantial homology to human caspase-3 and caspase-
8, was found to be essential for the elimination of distinct cells during embryogenesis (Horvitz et 
al., 1999). Mammalian caspases can be sub-divided according to their function, the length of their 
pro-domain, their substrate preference or phylogenetic relationship. Caspases in addition to their 
major role in apoptotic cell death also participate in other cellular processes such as proliferation, 
differentiation, development, inflammation and aging. Functionally are caspases divided into two 
major groups – pro-apoptotic and pro-inflammatory (Fig. 1.1, Shalini et al., 2015). The apoptotic 
caspases are sub-divided into a long prodomain-containing initiator caspases and short prodomain 
effector caspases. The activation and activity of the initiator caspases is usually required for the 
cleavage and thus activation of the effector caspases. Initiator caspases exist as inactive monomers 
and can be activated by proximity-catalysed self-processing in specific multimeric complexes 
(Oberst et al. 2010). Among the mammalian initiator caspases can be distinguished two sub-groups 
with different N-terminal prodomains. These domains typically mediate homotypic protein-protein 
interactions with other proteins participating in the caspase-activation platforms (Kersse et al., 
2011). CARD (caspase activation and recruitment domain) domain-containing caspase-9 binds 
through this domain to the apoptosome forming protein Apaf-1 and caspase-2 interacts via CARD 
domain with the PIDDosome adapter protein RAIDD. DED domain (death effector domain) in 
caspases-8 and -10 serves to mediate their interaction with another adapter protein FADD (Fas 
associated death domain protein). The different type of prodomain predicts the different kind of 
apoptotic pathway involvement. The first two caspases - caspase-9 or caspase-2 have function in 
the intrinsic/mitochondrial apoptosis and are activated in the Apaf-1 forming apoptosome or in 
PIDD-containing PIDDosome, respectively. The latter two caspase - caspase-8 and caspase-10 
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have function in the ligand induced/extrinsic apoptosis and are activated at the DISC complex 
(death inducing signalling complex) – especially caspase-8 (Shalini et al., 2015). 
 
 
 
Figure 1.1: The structure and classification of mammalian caspases. CARD (caspase 
recruitment domain), DED (death effector domain), L stands for large domain, S stands for small 
domain. Adapted from Shalini et al., 2015. 
      The effector caspases-3/6/7 do not contain N-terminal protein-protein interaction domains and 
are expressed as inactive dimers. They are activated by their processing with the initiator caspases 
(3/7) or some other proteases (e.g. granzyme B). Caspase-6 is cleaved by caspase 3 and -7 (Green 
and Llambi, 2015). Cleavage between large (L in Fig. 1.1) and small (S in Fig. 1.1) domain and 
cleaving off the short N-terminal prodomain leads to forming the tetramer consisting of two small 
and two large subunits. Thus activated effector caspases cleave crucial regulatory and structural 
proteins, causing disassembly of the cell with the typical morphological features (Table 1) 
(Salvesen and Riedl, 2008; Crawford and Wells, 2011). Activation and activity of both initiator 
and effector caspases can be regulated by post-translational modifications (largely by 
phosphorylation), their stability and through the interaction with regulatory proteins. There are 
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many regulatory proteins which act upstream of the caspase activation and decide whether the cell 
survive or commit suicide. Among them the most important caspase regulators are IAP proteins 
(more in chapter 1.1.1.3 Negative regulation of apoptosis by IAP proteins and cFLIP). They can 
regulate not only activation of the caspases but can also directly compete for the binding of the 
caspases and regulate their activity by ubiquitin-ligase dependent manner (Dubrez-Daloz et al., 
2008). 
     In addition to the essential role of caspases in apoptosis, these proteases participate also in other 
cellular events. They play and important role in regulation of dynamic of actin filaments, cell 
proliferation, differentiation, cell survival, inflammation or innate immunity. In these processes 
the activation of caspases is time-and space-limited and usually occurs without concomitant 
induction of cell death. Activation and activity of caspases is a very complex process and there 
were identified many cell and viral regulatory proteins which control their activity in apoptotic as 
well as non-apoptotic processes (Green and Llambi, 2015). 
 
1.1.1.2 Mechanism of apoptotic signalling pathway 
     Apoptosis is energy-dependent process leading to the efficient dismantling of the cell with the 
minimal pro-inflammatory leakage of intracellular content and effective removal of apoptotic 
corpses. Apoptotic cascade is in mammals induced by two general pathways: the extrinsic and 
intrinsic pathway (Fig. 1.3) (Ashkenazi et al., 1998; Igney et al., 2002). In addition, the cytotoxic 
T cells exploit so-called perforin/granzyme signalling that can induce apoptosis-like cell death via 
injection of granzyme serine proteases (A, B, etc.). The extrinsic, intrinsic and granzyme B 
pathways have different initiation steps but leads to the activation of same group of effector 
caspases resulting in morphological and biochemical features of caspase-dependent apoptosis 
(Martinvalet et al., 2005). 
     The extrinsic apoptotic signalling mainly relies on ligand-receptor mediated interaction. The 
most studied and well known are pro-apoptotic ligands of the tumour necrosis family or TNF 
ligand family (TNFα, FasL, Apo2L/TRAIL), which bind to their cognate receptors of TNFR 
receptor family (TNFR1/2, FasR/CD95, TRAIL receptors). Members of the TNFR family share 
homology in the extracellular cysteine-rich domains (the ligand binding pocket) and some of them 
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so-called “death receptors” also in their cytoplasmic domain containing α-helical protein-protein 
interaction region called death domain (DD) (Ashkenazi et al., 1998).  
     One of the best characterized death ligand-receptor pair inducing extrinsic apoptosis is 
TNFα/TNFR1. TNFα is a trimeric cytokine produced by number of cells though mainly by 
activated macrophages in response to cellular stresses such as inflammation, infection or injury. 
After binding to the receptor TNFR1, TNFα triggers the conformational changes, which lead to 
the recruitment of the adaptor protein TNF receptor-associated death domain (TRADD) via its 
own death domain. TRADD serves as a platform for recruiting other proteins as receptor-
interacting protein 1 (RIP1), TNF-receptor-associated factor 2 (TRAF2) and others (Grimm et al., 
1996; Wajant et al., 2002). Signalling from the activated TNFR1 receptor can proceed through the 
membrane-associated complex and multifunctional cytoplasmic complexes (Fig. 1.2, Lafont et al., 
2018). The first, membrane bound complex I consisting mainly of TNFR1, RIP1, TRADD, 
TRAF2, cIAP1/2, TAK1, HOIP-HOIL, SHARPIN and other proteins, induce activation of NFκB 
and JNK pathways. The intracellular cytoplasmic complexes can trigger both apoptosis and 
necroptosis (see also 1.1.2 Necroptosis) (Micheau and Tschopp, 2003). The core of apoptosis-
inducing complex consists of RIP1, TRADD, FADD and caspase-8. Caspase-8 is recruited to the 
complex by the interaction with the adaptor protein FADD via their DED domain. Proximity-
induced activation of caspase-8 leads to the autocatalytic cleavage of caspase and its full activation 
(Dickens et al., 2012). Activated caspase-8 cleaves and activates the downstream substrates, 
among them the most important BH3-only protein Bid and effector caspase-3/7. Truncated Bid 
(tBid) serves as an interconnection between extrinsic and intrinsic apoptosis in type II cells, which 
in contrast with type I cells, require mitochondrial amplification of apoptotic signalling for 
efficient induction of apoptosis. tBid blocks anti-apoptotic proteins such as Bcl-2 or Bcl-XL and 
co-activates pro-apoptotic Bcl-2 proteins Bax and Bak, resulting in the mitochondria-outer 
membrane permeabilization (MOMP) and downstream activation of intrinsic apoptotic signalling. 
Caspase-8 can activate effector caspases directly by their cleavage or indirectly through tBid and 
mitochondria-mediated cell death. Activity of caspase-8 could be inhibited by cFLIP protein that 
resembles caspase-8 but does not possess full catalytic domain and can compete with caspase-8 
for binding of adaptor protein FADD (Green and Llambi, 2015).  
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Figure 1.2: Different protein complexes formed in TNFα induced signalling. Membrane-
associated Complex I leads to activation of pro-survival pathways while cytoplasmic Complex II 
can lead to apoptosis or necroptosis.  Adapted from Lafont et al., 2018. 
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     Mitochondrial or intrinsic pathway could be activated without receptor-mediated stimuli and is 
triggered by diverse signals that directly activate intracellular targets involved in the mitochondria-
initiated events. Among the signals inducing intrinsic apoptosis belong negative: the absence of 
growth factors, hormones or cytokines, as well as positive signals: radiation, hypoxia, thermal 
stress, viral infections or free radicals. These stress signals activate or induce expression of pro-
apoptotic BH3-only Bcl-2 proteins such as Bid, Bim, Puma and others which directly and/or 
indirectly (through inactivating anti-apoptotic Bcl-2 proteins) trigger Bax and Bak homo- and 
hetero-oligomerization in the mitochondrial outer membrane and its pore-assisted 
permeabilisation (Kale et al., 2018). The permeabilisation of the outer mitochondrial membrane 
releases two groups of apoptosis promoting regulatory proteins from the inter-membrane space of 
mitochondria into the cytosol. First group is consisting of cytochrome c, SMAC/DIABLO and 
protease HtrA2/Omi. In the cytosol, cytochrome c binds and activates Apaf-1 protein leading to 
its oligomerization and forming of the apoptosome complex (Du et al., 2000; van Loo et al., 2002). 
This arrangement is formed by seven monomers of Apaf-1 set in one ring (Acehan et al., 2002). 
Apoptosome forming is dATP-dependent process. The apoptosome serves as a docking site for 
activation of initiator caspase-9. Apaf-1 protein contains in addition to the interaction CARD 
domain also WD40 repeats, which in mammals have the auto-inhibitory function of blocking 
CARD/CARD domain interaction of APAF-1 and caspase-9 in non-apoptotic condition. In case 
of pro-apoptotic stimuli and cytochrome c release from the inter-membrane space of mitochondria, 
cytochrome c binds to WD40 domain and causes the conformational change that leads to opening 
of CARD domain for the interaction with caspase-9 (Hill et al., 2004). Smac/DIABLO and 
HtrA2/Omi are inhibitors of IAP proteins (inhibitors of apoptosis), thus clearing out a way for full 
unhampered activity of caspase-9 as well as effector caspases-3 and 7 (van Loo et al., 2002; 
Schimmer et al., 2004). The second group of pro-apoptotic proteins released in late phase of 
mitochondria mediated cell death are AIF (apoptosis inducing factor) and endonuclease G. These 
proteins translocate to the nucleus where firstly AIF cause DNA fragmentation into 50~300 bp and 
condensation of chromatin and endonuclease G cleave chromatin and produce oligonucleosomal 
DNA fragments (Joza et al. 2001; Li et al. 2001). Concurrently nuclease CAD (caspase-activated 
DNase) is activated by caspase-3 through cleavage of its inhibitor ICAD and also cleaves DNA 
and induces higher chromatin condensation in the nucleus (Enari et al, 1998; Joza et al., 2001; Li 
et al., 2001). 
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Figure 1.3: Basic model of extrinsic and intrinsic apoptotic pathway. Adapted from de 
Almagro and Vucic, 2012.  
 
1.1.1.3 Negative regulation of apoptosis by IAP proteins and cFLIP 
    Among the negative regulators of apoptosis belongs the family of IAP proteins (inhibitors of 
apoptosis) or also called BIRC (baculovirus IAP repeat BIR containing) proteins. This group of 
evolutionary conserved proteins was initially identified in genome of baculoviruses as their 
protection against host-defence apoptotic signalling triggered by viral infection. The first and one 
of the most important IAP proteins identified in human cells was XIAP, discovered by searching 
for the BIR domain homology sequence. The function of the c-IAP (cellular IAP) proteins in the 
human cells is very diverse and involves not only cell death as apoptosis or necroptosis, but also 
regulate cell migration and cell survival through cell cycle, immunity and inflammation (NAIP, 
survivin, Apollon/Bruce, ILP-2) (de Almagro and Vucic, 2012). 
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     IAPs share several well conserved protein domains which determine their activity such as N-
terminal BIR domains. Their function is to mediate protein-protein interactions and more copies 
of this domain enable the robust binding character and functions of IAPs in the cell (Eckelman et 
al., 2006). The specific sequence of BIR1 domain in c-IAP1 and c-IAP2 enables them to bind 
TRAF1/2 adaptor protein in case of TNF ligand family induced signalling. The second conserved 
domain that is present in some IAPs, e.g. in cIAP1/2 or XIAP, is a RING domain (C-terminal Ring 
zinc-finger, RING- Really Interesting New Gene), which acts as E3 ubiquitin ligase and could 
target IAPs itself and IAP-interacting proteins to the proteosomal degradation. Also the IAP-
binding proteins possess N-terminal IAP binding motif, which could be found in plethora of 
proteins involved in apoptosis as for example caspase-9, Smac/DIABLO or Omi/HtrA2 (Palaga et 
al., 2002; Vaux et al., 2003). 
     There are two main ways how IAP proteins regulate cell signalling, either in case of XIAP by 
direct binding-mediated inhibition of active caspases-3/7/9 or for cIAP-1 and cIAP-2 by the E3 
ligase activity and modulation of signalling induced by ligands from the TNF family. The most 
important substrates for the polyubiquitination by c-IAPs is RIP1 kinase and NIK, both acting in 
the activation of canonical and non-canonical NFκB signalling. The ubiquitination of other targets 
as TRAF2, TRAF3 and Smac/DIABLO could have a direct impact on cell survival. XIAP E3 
ligase activity is not essential for its anti-apoptotic function but can modulate the fate of the cell. 
IAPs anti-apoptotic function could be blocked by binding of Smac or Omi/HtrA2 which are 
released during mitochondria induced apoptosis. Omi/HtrA2 has a dual function because it not 
only compete with caspases for the binding of XIAP, but also has a serine-protease activity and 
cleaves XIAP to non-functional protein. As far as the main function of IAP proteins is to maintain 
cell survival not only by inhibiting the apoptosis but also inducing NFκB and MAPK pro-survival 
pathway, these proteins are overexpressed in many tumours, e.g. colon and cervical tumours 
(cIAP1/2), breast cancer (XIAP) and myeloma (cIAP, XIAP, survivin) (Ali et al., 2018; Lalaoui 
et al., 2018).  
      Very important anti-apoptotic protein specific for the receptor or extrinsic apoptosis is an 
„inactive caspase“ cFLIP protein. FLIP was firstly identified in viruses as a viral escape 
mechanism against the host cell-induced apoptosis (Thome et al., 1997). Later it was mapped in 
the human genome as the CFLAR gene and its product cellular FLIP or cFLIP has three major 
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isoforms: cFLIP-L (55 kDa), cFLIP-R (25kDa) and cFLIP-S (27 kDa) (Fig. 1.4) (Micheau et al., 
2001). Although cFLIP-L possess the greatest similarity to the sequence of caspase-8, it is 
proteolytically inactive due to the absence of catalytically important residues. The other two forms 
do not contain the caspase-like domain (C-terminal domain) but all three isoforms have two DED 
domains and interact with FADD and caspase-8 at the receptor level (Hu et al., 1997; Rasper et 
al., 1998). While cFLIP-R/S simply inhibit caspase-8 activation by heterodimerization with the 
molecules of caspase at the receptor level, cFLIP-L seems to have also other than just inhibitory 
role in DR-triggered signalling. Indeed, cFLIP-L can at high levels inhibit apoptosis in similar way 
as short splice variants of cFLIP, but as far as it can form heterodimers with caspase-8, in low ratio 
to caspase-8 it can enhance recruitment of pro-caspase-8 molecules to DISC (Boatright et al., 
2004). Heterodimerization of caspase-8 with cFLIP is additionally advanced by caspase-8-
mediated cleavage in the cFLIP-L interdomain (Krueger et al., 2001; Chang et al., 2002; Micheau 
et al., 2002; Pop et al., 2011). Interestingly, the N-terminal prodomain generated by full cleavage 
of caspase-8 and structurally similar to cFLIP-R/S, remains at DISC and terminates procaspase-8 
activation in a feedback loop (Schleich et al., 2016).   
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Figure 1.4: Structure of human CFLAR gene and protein cFLIP. The red arrow indicates 
CFLAR gene, the black arrows indicate nearby genes on human chromosome 2q33-34. The yellow 
box indicates caspase-8 like domain, the magenta box is DED interaction domain. Top three 
depicted proteins are different splice variants of CFLAR gene and two bottom ones are products 
of caspase-8 cleavage. Adapted from Tsuchiya et al., 2015. 
 
1.1.1.4 Regulation of apoptosis by proteins from the Bcl-2 family 
     In mammalian cells, the members of this protein group form a large family. They are best 
known as both regulators and inducers of apoptosis with pro- as well as anti-apoptotic functions. 
Human Bcl-2 (B-cell lymphoma gene 2) was discovered as a proto-oncogene in B-cell lymphoma 
cells (Tsujimoto et al., 1985). The first identified pro-apoptotic member of this family was protein 
Bax (Bcl-2 associated protein X) (Oltvai et al., 1993). Although the sequence homology in this 
protein family is not obvious, the Bcl-2 proteins do have four conserved domains, which are known 
as Bcl-2 Homology- BH (1-4) domains (Fig. 1.5). These domains are essential not only for the 
protein-protein interaction, but also for the activity of Bcl-2 proteins (Yin et al., 1994). In addition, 
most members of this protein family contain also a C-terminal hydrophobic domain (membrane 
anchor domain), important for their targeting to intracellular lipid membranes (mainly 
mitochondria and endoplasmatic reticulum) (Antonsson et al., 2004). 
     All anti-apoptotic proteins from Bcl-2 family have all four BH domains but differ in their 
cellular localisation. While Bcl-2 itself is predominantly localised in the membranes, including the 
outer mitochondrial membrane (OMM), endoplasmatic reticulum and nuclear membrane, Bcl-XL 
and Mcl-1 do localize both in the cytoplasm and OMM or ER (Bcl-XL) membranes (Kale et al., 
2018). The pro-apoptotic Bcl-2 family proteins can be divided into two main groups. The first one 
contains multidomain proteins Bax, Bak and Bok. The intracellular localisation of Bax and Bak is 
different. While Bak is mostly associated with the outer mitochondrial membrane, Bax can be also 
found in cytoplasm interacting e.g. with 14-3-3 proteins (Goping et al., 1998; Eskes et al., 2000). 
The multi-domain pro-apoptotic proteins Bax and Bak are in normal condition in inactive form 
and became activated upon various stimuli including posttranslational modifications. Upon these 
stimuli they undergo conformational change in the OMM where they can form large protein-
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permeable pores (Goping et al., 1998). Through these pores a number of pro-apoptotic proteins is 
released from the mitochondrial intermembrane space including cytochrome c, Smac, HtrA2, 
endonucleases G and AIF (Li et al., 1998; Lassus et al., 2002; Li et al., 2002). The second more 
numerous group of pro-apoptotic Bcl-2 proteins are BH-3 only proteins, which are activated by 
pro-apoptotic (stress) signals at multiple levels. Upon their activation they translocate to 
mitochondria and interact with anti-apoptotic Bcl-2 proteins attenuating or blocking their function. 
A small group of BH3-only proteins notably Bim, tBid and likely Puma can in addition to 
inhibiting anti-apoptotic Bcl-2 proteins also interact with pro-apoptotic Bax and Bak proteins and 
enhance their oligomerization and pore formation in the OMM (Eskes et al., 2000; Adams and 
Cory, 2018; Kale et al., 2018; Pentimalli et al., 2018).  
 
 
Figure 1.5: Bcl-2 protein family. Different groups of Bcl-2 proteins and their BH domains 
divided according to their function in apoptosis. Adapted from Adams and Cory, 2018. 
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1.1.2 Necroptosis 
     Necrosis was recognized as a mode of non-programmed accidental cell death from the mid of 
the 19th century. In last decades it has been revealed that necrosis could be under some 
circumstances induced by defined signalling pathways and thus recognized as another regulated 
mode of cell death. One of the best characterized pathways of regulated necrosis is so-called 
necroptosis. According to the recent nomenclature is the term necroptosis defined as a necrotic 
type of cell death dependent on receptor-interacting protein kinase-3 (RIPK3) (Galluzzi et al. 
2018). Necroptosis triggered by activated receptor-interacting protein kinase 1 (RIPK1) (upstream 
of RIPK3) could be inhibited by chemical inhibitors (e. g. necrostatin-1, Nec-1) or at the level of 
gene expression of key signalling molecules (such as RIPK3) involved in necroptotic machinery 
(Vercammen et al., 1998; Degterev et al., 2005; Degterev et al. 2008; Zhang et al., 2009; Sun et 
al., 2012). It has the morphological features of necrosis with the rounded and swelling cell 
(oncosis), cytoplasmic vacuolisation, rupture of mitochondria and lysosomal organelles, 
breakdown of plasma membrane, release of the intracellular content and induction of typical 
inflammatory response (Krysko et al., 2008). 
     While apoptosis has a clearly important role during embryonic development, the physiological 
role of regulated necrosis is more obscure. However, it looks like that this specific mode of 
regulated necrosis-necroptosis can participate in cell death induction in various pathophysiological 
conditions. Necroptosis could be triggered on the cellular level by plethora of signals as: TNFα, 
FasL, TRAIL ligand, lipopolysaccharide, dsRNA, DNA damage, endoplasmatic reticulum stress, 
viral infection and anti-cancer drugs (Vercammen et al., 1998; Holler et al., 2000; Cho et al., 2009; 
He et al., 2011; Tenev et al., 2011; Jouan-Lanhouet et al., 2012; Thapa et al., 2013; Saveljeva et 
al., 2015).  
    TNFα-induced signalling from the TNFR1 receptor was instrumental for the discovery and 
further research of necroptosis. As is shown in Fig. 1.2 and also in Fig. 1.6, the ligation of TNFα 
ligand to its cognate receptor TNFR1 could induce several signalling pathways, where different 
types of protein complexes are formed depending on the upstream pro-survival or pro-death signal 
(Grootjans et al., 2017). At the molecular signalling level the TNFα interaction with TNFR1 
receptor induces recruitment of RIPK1 and adaptor protein TRADD via their death domains with 
two main possible complexes: complex I and complex II. In “closed conformation” the RIPK1 is 
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ubiquitinated by cIAP1/2 and phosphorylated by IKK complex, which prevents its dissociation 
from the receptor forming complex I (the core of NFκB signalling), or RIPK1 is not ubiquitinated 
(“opened conformation”) or is de-ubiquitinated (for example by A20 or CYLD enzyme or by using 
the inhibitors of Smac mimetics) and the cytosolic complex II a/b consisting of RIPK1, FADD, 
caspase-8 with or without the adapter protein TRADD forms. Both of the complexes II a/b lead to 
the activation of caspase-8-dependent apoptosis. In first case, complex IIa leads to the RIPK1-
independent apoptosis. The second complex IIb is formed in case when cIAPs, TAK1 or IKK 
complex is inactive or absent and the RIPK1 kinase activity becomes inevitable for proceeding of 
further apoptosis. Activated caspase-8 cleaves in addition to other proteins also both RIP kinases 
and thus suppresses induction of necroptosis. However, when protease activity of caspase-8 is 
impaired, the necrosome complex containing RIPK1/3 is formed. The kinase activity and the 
opened form of RIPK1 is essential for the activation and auto-phosphorylation of RIPK3. Although 
the RIPK3 is phosphorylated at Ser227 in a Nec-1 inhibitable manner, it was shown in vitro that 
RIPK1 is unable to phosphorylate RIPK3. Therefore, the phosphorylation of this kinase is not the 
trans-phosphorylation as was once thought, but most probably it is the auto-phosphorylation of the 
RIPK3 kinase itself, which is at least for TNFα-induced necroptosis, dependent on its interaction 
with RIPK1. Nevertheless necrosome formation promotes further activation of RIPK3, forming of 
oligo-amyloid like structures of RHIM domain-containing protein aggregates and RIPK3-
dependent phosphorylation and subsequent activation of the mixed linage kinase-like protein 
(MLKL). p-MLKL translocates to cellular membranes via its interaction with phosphatidyl inositol 
phosphates (PIP)  and either directly by forming pores into the plasma membrane or indirectly 
through the activation of ion channels induce permeabilization of the plasma membrane and 
activate the execution phase of necroptosis (Micheau et al., 2003; Zheng et al., 2006; Wang et al., 
2008; Pasparakis et al., 2015).  
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Figure 1.6: Necroptosis and other signalling pathways induced by TNFα ligand. (a) TNFα 
stimulation leads to forming of pro-survival Complex I. Ubiquitinated RIPK1 recruits the proteins 
of TAK1 kinase cascade and IKK complex resulting in the activation of MAPK and NFκB 
pathways. (b) RIPK1 dissociates from the TNFR1 receptor and forms two types of apoptotic 
complexes IIa and IIb or in case of caspase-8 inhibition/inactivation or absence forms the 
necrosome complex involved in the process of necroptosis. Downstream the phosphorylated 
protein RIPK1 induces auto-phosphorylation of RIPK3 which phosphorylates MLKL protein 
leading to execution part of the necroptosis. Adapted from Grootjans et al., 2017. 
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     As shown in Fig. 1.6, there are several signalling molecules shared in different signalling 
complexes. One of the most important is the RIPK1 kinase, which could represent a switch point 
of the TNFα ligand signalling pathway of necroptosis and plays similar role also in TRAIL and 
FasL- induced necroptotic signalling (Holler et al., 2000). This kinase has several very important 
domains involved in different signalling pathways thus deciding the cell fate (Fig. 1.7). The N-
terminal kinase domain is important for the induction of cell death in both RIPK1 dependent 
apoptosis and necroptosis. The intermediary domain ID plays role in post-translational 
modification of the RIPK1 where it serves as a scaffold for further K63 and M1 ubiquitination 
resulting in the activation of JNK, p38, ERK and NF-κB pathway (for more information see 
chapter: 1.2.4 Non-canonical TRAIL induced signalling). The C-terminal death domain DD is a 
classical protein-protein interaction domain involved in the induction of apoptosis, serving for the 
recruitment of other components of the apoptotic machinery, namely FADD and caspase-8. The 
last one is the C-terminal RHIM domain (RIP homotypic interaction motif), which could be found 
also in other necroptosis-involved proteins and it serves as a protein-protein interaction domain 
with not only downstream target kinase RIPK3 but also with other RHIM-containing proteins 
(Chen et al., 2002; Sun et al., 2002; Festjens et al., 2007; Dondelinger et al., 2013; Pasparakis et 
al., 2015). RIPK1 shares 33% similarity with the kinase RIPK3, which also contains N-terminal 
kinase domain, intermediate domain and important C-terminal RHIM domain interacting with 
RIPK1. According to the most studies it seems that RIPK3 kinase activity is indispensable for the 
induction of necroptosis (Festjens et al., 2007; Dondelinger et al., 2013). The last key mediator of 
necroptosis is a pseudo kinase, mixed lineage kinase like, MLKL protein. This protein is likely the 
main effector of necroptosis (Zhao et al., 2012). MLKL also possess inactive kinase domain, thus 
the main function part of this protein is the N-terminal 4HB domain, which when phosphorylated 
by RIPK3 brings MLKL to the plasma membrane through PIP binding, causing pore formation 
and plasma membrane permeabilisation. RIPK3 and MLKL bind through their kinase domains and 
presumably they exist in the pre-assembled non-active complexes (Xie et al., 2013). 
Phosphorylation of MLKL by RIPK3 is an essential step for the next conformational change and 
opening of HB domain (Murphy et al., 2013). Interestingly, RIPK3 can phosphorylate also other 
substrate, the calcium-dependent protein kinase II delta or CAMK2D and it looks like that this 
kinase is able in some special cases through the direct or indirect activation of calcium, potassium 
and natrium ion channels induce necroptosis independently on MLKL protein (Ashpole et al., 
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2012; Zhang et al., 2016; Zhang et al., 2018). The canonical RIPK1/RIPK3-containing necrosome 
is associated with necroptosis induced by several types of stimuli: ligation of death receptors 
(TNFR 1/2, FasR, TRAILR 1/2); stimulation of the pathogen recognition receptor family (PRR) 
expressed by cells of innate immune system to sense pathogen-associated molecular patterns 
(PAMPS), which includes membrane bound Toll-like receptors (TLR 2, 4, 5 and 9), cytosolic 
NOD-like receptors  and retinoic acid induced gene 1-like receptors; activation of T-cell receptor; 
using anti-cancer drugs (Smac mimetics), vaccinia infection; IFN, DNA damage and many others 
(Holler et al., 2000; Cho et al., 2009; He et al., 2011; Tenev et al., 2011; Basit et al., 2013; Thapa 
et al., 2013). In some cases the autocrine TNFα secretion can boost necroptotic cell death 
(McNamara et al., 2013). In RIPK1 kinase-independent formation of so-called non-canonical 
necrosome, RHIM-containing adapter proteins TRIF (CMV infection) or the sensor ZBP1/DAI 
participate in RIPK3 activation and the induction of necroptosis (Kaiser et al., 2005; Kaiser et al., 
2013). It is possible that these proteins serves as a scaffold for the RIPK3 molecules recruitment, 
activation and auto-phosphorylation (Rebsamen et al., 2009). 
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 Figure 1.7: The structure of RHIM domain containing proteins involved in the process of 
necroptosis. Length is indicated in number of amino acids. KD - kinase domain, ID - intermediate 
domain, DD- death domain, RHIM- RIP homotypic interaction motif, TIR- Toll/interleukin 
receptor domain, 4 HB- four helical bundle domain, BR- brace region, CB- calmodulin-binding 
domain, RIPK - receptor interacting kinase, ZBP1- Z-DNA-binding protein 1, TRIF - TIR-domain 
containing adaptor-inducing IFN-beta, MLKL - mixed lineage kinase domain-like protein, 
CAMK2D- calcium/calmodulin-dependent protein kinase type II subunit delta. Adapted and 
adjusted from Grootjans et al., 2017. 
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1.2 TRAIL induced signalling 
1.2.1 TRAIL and the ligands from TNF family  
    TNFα or tumour necrosis factor is a canonical “death ligand” of the TNF super-family (TNFSF), 
where also TRAIL (Apo2L) and CD95 ligand (FasL or Apo1L) belong. These prominent executors 
of extrinsic apoptosis can in addition induce proliferation and survival of normal as well as cancer 
cells (von Karstedt et al., 2017). They are expressed mainly in the cells of immune system and are 
associated with the protective function of these cells. Tumour killing activity induced by bacterial 
infection was known from the beginning of 20th century and later was TNFα ligand identified as 
the one responsible for this process (Carswell et al., 1975). However, systemic treatment with 
TNFα ligand led to the lethal inflammatory shock syndrome (Tracey et al., 1988). Similarly also 
use of other member of TNF family, Fas ligand (or its agonists), which has the same robust anti-
tumour killing capability, was severely hepatotoxic in mice (Ogasawara et al., 1993). Interestingly 
the third member of this group TRAIL ligand or TNF-related apoptosis inducing ligand (Apo2L, 
TNFSF10) was shown to induce apoptosis selectively in cancer cells in vitro and in vivo and didn´t 
manifest any lethal adverse effects encountered with TNFα or Fas ligand (Ashkenazi et al., 1999; 
Walczak et al., 1999). TRAIL was firstly identified in 1995 based on the homology sequence to 
the other members of the TNFSF. It has 23% homology to TNFα ligand and 28% homology to 
FasL (Wiley et al., 1995). Members of TNFSF can be expressed as soluble proteins as 
lymphotoxin-α and vascular endothelial growth inhibitor (TNFSF15) or as all other members are 
expressed as type II transmembrane proteins with one transmembrane domain, N-terminus facing 
to the cytosol and extracellular C-terminus of the protein. TNFα, CD95 and TRAIL ligand could 
also exist in a soluble form, which results from their cleavage from the cell surface in the process 
called shedding. In contrast with FasL and TNFα, where a disintegrin and metallo-proteinase 
domain-containing protein 10 (ADAM10) and ADAM17 were identified to cause the shedding of 
the ligands, in case of TRAIL is the identity of the responsible proteases unknown (von Karstedt 
et al., 2017). It was also shown that production of soluble TRAIL is dependent on the activity of 
cysteine proteases (Mariani and Krammer, 1998). TRAIL is present in the plasma of a healthy 
adult at app. 100 pg/ml, which is too low to induce any apoptosis in most cells in vitro. However 
liposome-bound TRAIL can kill cancer cells more efficiently than a soluble protein (Gibellini et 
al., 2007; De Miguel et al., 2013; Nair et al., 2015). Unlike other TNF family members, which 
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expression is tightly regulated and are often transiently expressed on activated cells, TRAIL is 
constitutively expressed mostly by the cells of the immune system. In these cells TRAIL 
participates in homeostasis of specific T cells, in NK and T-cell mediated killing of virus-infected 
or transformed cells (Martinez-Lorenzo et al., 1998; Kayagaki et al., 1999; Smyth et al., 2003). 
Human TRAIL contains of 281 amino acids (114-281 in cleaved form) and harbours 65% of the 
sequence identity with its 291 amino acids long murine homolog. According to the crystal structure 
for TRAIL/TRAIL-R2 complex, TRAIL likely as other TNF family ligands appears as a trimer. 
Homotrimeric TRAIL ligand is stabilised by an intern zinc ion in a non-covalent interaction with 
cysteine residues from each TRAIL monomer. This interaction was shown to be essential for its 
stability, solubility and biological activity (Hymowitz et al., 1999; Hymowitz et al., 2000). TNFR 
receptors signal as trimers as well and it was originally thought that the receptor trimerisation was 
induced by ligand binding. This presumption was challenged when a specific ligand-independent 
domain called pre-ligand assembly domain (PLAD)  has been identified (Chan et al., 2000). Thus 
some of the ligand trimers don´t induce the trimerisation but they can already bind to the existing 
receptor trimeric complexes, clustering into higher multimeric complexes (Lewis et al., 2012; 
Valley et al., 2012).  
1.2.2 TRAIL receptors 
     Human TRAIL interacts with five receptors: four membrane receptors TRAIL-R1, -R2, -R3, -
R4 and one soluble receptor OPG. TRAIL-R1 (DR4, TNFRSF10A) and -R2 (DR5, TNFRSF10B) 
are considered as pro-apoptotic and are receptor type I transmembrane proteins, homologous to 
other members of TNFR family. They share significant sequence homology with TNFR1 and 
CD95 in their death (DD) domain- containing cytoplasmic part. Other common features are the 
cysteine-rich domains (CRDs) in the extracellular portion of these receptors that form the ligand 
binding pocket. TRAIL-R4 (DcR2, TNFRSF10D) is also a receptor type I transmembrane protein 
but unlikely to DR4 and DR5 has a truncated death domain and thus is unable to transduce the 
apoptotic signal into the cell. TRAIL-R3 (DcR1, TNFRSF10C) lacks the cytoplasmic domain at 
all and is bound to the cell surface by GPI anchor (Fig. 1.8, von Karstedt et al., 2017). The exact 
physiological role of DcR1 and DcR2 is not yet known, but there are several experimental data-
based hypotheses. The obvious one is that they work as decoy receptors and compete with pro-
apoptotic receptors for TRAIL binding. However, this squelching activity of both receptors was 
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only documented in in vitro overexpression studies and moreover they do not possess higher 
affinity for TRAIL ligand comparing to DR4 and DR5 receptors (Merino et al., 2006). At 37°C 
TRAIL binds to TRAIL-R2 with the highest affinity than other membrane bound receptors, which 
is likely to be physiologically relevant especially under a limited supply of TRAIL ligand (Truneh 
et al., 2000). The decoy function of decoy receptors could be also addressed by the forming of 
mixed receptor complexes with the two pro-apoptotic receptors DR4/5, thus leading to the 
ineffective DISC formation. This formation of heteromeric TRAIL receptors could be mediated 
by pre-ligand assembly domain (Chan et al., 2000). In this mechanism the competition for TRAIL 
binding plays no direct role and could explain difference between decoy activity and their affinity 
for TRAIL ligand.  The second hypothesis is related to their non-apoptotic signalling and it was 
shown that at least the truncated TRAIL-R4 can activate pro-survival NFκB pathway (Degli-
Esposti et al., 1997; Degli-Esposti, 1999). Nevertheless as mentioned above, most of these 
experiments were done in overexpression systems and the physiological role of decoy receptors 
has to be established. Interestingly, TRAIL-R3 is highly expressed in primary gastrointestinal 
cancer and high expression of TRAIL-R4 is correlated with poor prognosis in breast cancer 
(Sheikh et al., 1999; Ganten et al., 2009). The fifth receptor which binds TRAIL ligand with the 
lowest affinity is secreted soluble receptor OPG (osteoprotegerin, TNFRSF11B) (Emery et al., 
1998). OPG mainly acts as a regulator of bone development and activation of osteoclastogenesis. 
This activity is, however, not influenced by TRAIL but RANK ligand that binds also to the RANK 
receptor involved in the activation of NFκB pathway (Kimberley et al., 2004). The role of OPG as 
a TRAIL receptor is not clear, it was suggested that it could also act as a decoy receptor in 
competing for TRAIL binding. TRAIL receptors have been mapped as a gene cluster on the 
chromosome 8p22-21 and their mRNA expression level shows that TRAIL-R1/-R2/-R4 have 
widespread expression, while TRAIL-R3 transcripts were restricted to the peripheral blood and 
spleen (Degli-Esposti et al., 1997). 
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Figure 1.8: Graphic representation of human and mouse TRAIL receptors and their protein 
domains. Human cells express two pro-apoptotic TRAIL receptors: TRAIL-R1 (DR4) and 
TRAIL-R2 (DR5) and three non-apoptotic receptors: TRAIL-R3 (DcR1), TRAIL-R4 (DcR2) and 
OPG. On the contrary there is only one pro-apoptotic TRAIL receptor expressed in mice mTRAIL-
R, accompanied by two decoy receptors mDcTRAIL-R1 and mDcTRAIL-R2 and mOPG. All of 
these receptors contain extracellular CRD which forms the binding pocket for TRAIL ligand. Pro-
apoptotic TRAIL-R1/R2 and mTRAIL-R contain in their intracellular parts the death domain 
(DD), which main function is to recruit adaptor protein FADD. TRAIL-R4 contains truncated DD 
domain. TRAIL-R3 is a glycosylphosphatidylinositol (GPI) anchored protein. TAPE repeat 
(threonine, alanine, proline, glutamine) domain and MPD (membrane-proximal domain) are 
present in two isoforms of TRAIL-R2 receptor. TAPE repeat could be also found in TRAIL-R3 
and MPD is present in mTRAIL-R receptor. Adapted from Karstedt et al., 2017. 
 
     Though there is a significant amount of data reffering to the structure, signalling and function 
of TRAIL receptors, their precise physiological role and regulation still remains to be determined. 
It was initially thought that DR4 and DR5 receptor have the same interchangeable function, but 
nowadays we know that one receptor could be prioritized over the other and this is not always 
correlated to the expression level of the respective pro-apoptotic receptor. Both receptors share 
only 46-48 % of sequence homology. There are two different splice variants for DR5 receptor 
which differ in 29 amino acids located between the cysteine rich domain (CRD) and the 
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transmembrane domain, but there is no evidence of different functionality between these two 
variants (Wang and Jeng, 2000). In Ewing´s sarcoma cells was identified also a short DR4 isoform, 
in which the alternative splice variant lacks 158 amino acids within the extracellular-ligand binding 
region (CRD domain) and the overexpression of this protein increased efficacy of TRAIL-induced 
apoptosis in resistant cells by yet unknown mechanism (Picarda et al., 2012; van Roosmalen et al., 
2014). Notably, humans have two different pro-apoptotic TRAIL receptors, whereas mice have 
only one death inducing receptor, which is equally homologous to DR4 (43% of sequence 
homology) as well as to DR5 (49% of sequence homology) (Kelley et al., 2004; Kelley et al., 
2005).      
     Many factors could imply differences in signalization of DR4 and DR5 receptor. As mentioned 
above the presence of two death-inducing TRAIL receptors in human cells implicates an 
evolutionary advantage and low sequence similarity (~50%) suggests structural, functional and 
regulating differences. Moreover certain types of tumours could have preference in signalling for 
either of the DR receptors. This apparent preference could be the result of more regulation steps, 
mostly at the level of transcription, in addition affected by membrane DR4/5 localization, 
externalisation, post-translational modifications or the endocytosis of DISC upon TRAIL binding 
(Karstedt et al., 2017). Interestingly, epigenetic silencing of DR4 in melanoma, glioma and ovarian 
cancer cells caused TRAIL resistance in these tumour cells (Horak et al., 2005; Bae et al., 2008; 
Elias et al., 2009). Transcription factors as p53, NFκB, CHOP, FOXO3a and AP1, which are 
correlated to stress-induced apoptosis, can also regulate the expression of both TRAIL receptors 
(Baritaki et al., 2008; Kurita et al., 2010; Moon et al., 2010; van Roosmalen et al., 2014). Very 
interesting recent finding marks DR5 as a target of the UPR transcription factor CHOP and one of 
the pro-apoptotic proteins involved in ER stress-induced apoptosis (Lu et al., 2014). Even though 
the total protein level of TRAIL receptors can have an impact on TRAIL signalling, it is the cell 
surface expression which is required for their proper physiological function. The intracellular 
trafficking mechanisms play also an important role and for example downregulation of 
components of the signal recognition particle SRP72 and SRP 54 or downregulation of ARAP1 
was correlated to the reduction of cell surface levels of DR4 receptor and attenuated TRAIL-
triggered apoptosis (Ren et al. 2004; Simova et al., 2008). Moreover, activation of death receptors 
inhibits clathrin-dependent endocytosis (Austin et al., 2006). Post-translational modifications can 
also have a significant impact on the outcome of TRAIL-induced signalling. S-palmytoylation of 
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DR4 on the cysteine triplet (AA 261-263) near transmembrane domain or S-nitrosylation, the 
covalent coupling of nitrogen monoxide group to a reactive cysteine thiol in DR4, were shown to 
promote DR4-mediated apoptotic signalling (Tang et al., 2006; Rossin et al., 2009). Similarly O-
glycosylation of the extracellular parts of DR4 and DR5 attenuated TRAIL resistance of tumour 
cells, as also did N-glycosylation in DR4 (Wagner et al., 2007; Yoshida et al., 2007). Another 
important modification ubiquitination by MARCH-1/8 was found to target DR4 for lysosomal 
degradation thus regulating its cell surface levels (van de Kooij et al., 2013).   
1.2.3 Canonical signalling induced by ligand TRAIL 
     Upon binding of TRAIL ligand to its receptors, TRAIL induces formation of two signalling 
complexes: the initial membrane associated complex I or DISC (death inducing signalling 
complex) and the later, receptor-free cytosolic complex II. Unlike TNFα ligand both of these 
complexes can induce cell death (Lafont et al., 2017). Notably TRAIL-induced cell death does not 
include only caspase-dependent apoptosis, but also RIPK1/3-dependent necroptosis. However, 
when TRAIL-mediated death signalling is suppressed, the activation of auxiliary signalling 
pathways such as NFkB or MAP kinases can enhance tumour progression through boosting cell 
migration, proliferation, invasion and production of tumour-supportive cytokines (von Karstedt et 
al., 2017). 
1.2.3.1 Apoptosis 
     Binding of trimeric TRAIL to its trimeric pro-death receptors DR4 or DR5 induces their 
clustering and higher oligomerization in the cytoplasmic membrane. The concomitant 
conformational changes in their intracellular part leads to the recruitment of adaptor protein FADD 
via the DD homotypic interaction. FADD subsequently recruits the other components of DISC. 
Binding of FADD to the DISC complex exposes its DED domain for the interaction with DED 
domains of caspase-8/10 and cFLIP (Lafont et al., 2017; von Karstedt et al., 2017). There are 
several hypothesis how is the caspase-8 activated at the DISC level but nowadays is mainly 
accepted caspase-proximity cleavage model. In this model, the molecules of caspase-8 are 
activated by proximity-induced conformational change and via their DED interactions form 
clustered chains containing up to eight molecules of pro-caspase-8 per one molecule of FADD. In 
these chains the activated caspases process themselves initially cleaving of the small p10 subunits 
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forming p43/p10 dimers. These dimers are already highly active and can further process 
themselves or other associated proteins such as cFLIP-L or pro-caspase-10. In the final auto-
processing step the p18 subunit is cleaved off the p43 peptide and fully active (p18/p10)2 
heterotetramer of caspase-8 is released to cytoplasm, where it can cleave other target proteins such 
as Bid. (Dickens et al., 2012; Fu et al., 2016). Both caspases, caspase-8 and caspase-10 are 
recruited to the DISC but caspase-10 itself cannot substitute for caspase-8, which is thus essential 
for inducing of the death receptor-triggered apoptosis (Sprick et al., 2002). cFLIP acts mainly as 
an inhibitor of apoptosis, though under certain circumstances it can enhance caspase-8 processing 
(for more information see chapter 1.1.1.3 Negative regulation of apoptosis by IAP proteins and c-
FLIP). Recent data suggest a very important role of post-translational modification of caspase-8 
such as ubiquitination in the regulation of caspase-8 activity. It was shown that E3 ligase Cullin-3 
facilitates to caspase-8 aggregation by non-degradative ubiquitination of caspase-8, leading to 
enhanced clustering and stabilisation of caspase-8 molecules. In contrast, E3 ligase TRAF2-
mediated K48-linked ubiquitination of p18 subunit of active caspase-8 leads to rapid proteasomal 
degradation of caspase-8 (Jin et al., 2009; Gonzalvez et al., 2012).  
      TRAIL or FasL-induced apoptosis of permissive cells can be classified into two categories 
depending on the level of death receptor activation and on certain cellular factors.  In so-called 
type-I cells such as activated T cells massive activation of caspase-8 and absence of caspase 
inhibitors is sufficient for strong and steady activation of effector caspases and rapid caspase-
dependent apoptosis. However, majority of permissive cells (type II cells) does not fulfil these 
requirements due to low levels of activated caspase-8 and presence of caspase inhibitors such as 
XIAP and thus a successful progression of apoptosis requires mitochondrial amplification of 
apoptotic signalling. This amplification is orchestrated by caspase-8-mediated cleavage of BH3 
only protein Bid. Cleaved Bid or truncated Bid (tBid) is N-myristoylated and rapidly translocates 
to mitochondria where it blocks anti-apoptotic Bcl-2 family proteins and also participates in 
activation of the pro-apoptotic Bax and Bak, which subsequently cause the permeabilisation of the 
outer mitochondrial membrane and mitochondrial apoptotic signalling as described in part 1.1.1 
Apoptosis. Thus the critical factors for the distinction between these two types of cells is their 
efficiency in DISC formation and caspase-8 activation and also the cellular levels of the caspase-
3/9 inhibitor XIAP (Korsmeyer et al., 2000; Jost et al., 2009; Lemke et al., 2014). 
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Figure 1.9: TRAIL induced apoptosis in type I and type II cells. In type I cell lines is DISC-
activated caspase-8 capable to fully induce apoptosis through direct processing of the effector 
caspases such as caspase-3. In type II cells, activation of mitochondrial apoptotic signalling 
mediated by caspase-8-cleaved tBid enhances Bax/Bak-mediated MOMP and subsequent 
apoptotic signalling. TRAIL-induced apoptosis can be inhibited: (i) at the level of DISC, where 
cFLIP competes for binding of FADD with caspase-8, (ii) at the level of mitochondria, where anti-
apoptotic Bcl-2 proteins can suppress Bax/Bak activation and (iii) at the level of caspases, where 
XIAP can directly bind and inhibit caspases-3 and -9. Adapted from Lemke et al., 2014. 
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1.2.4 Non-canonical TRAIL-induced signalling 
 
1.2.4.1  Necroptosis   
     Necroptosis represents the most general mode of regulated necrosis, which is apparently 
involved in many pathophysiological processes and emerged as an alternative approach for 
elimination of cancer cells. TRAIL as one of the still promising anti-cancer agents can in addition 
to caspase-dependent apoptosis similarly as TNFα also induce necroptosis. TRAIL induced 
necroptosis is capable to reduce amount of cancer cells, but there are only a few studies concerning 
the TRAIL-mediated necroptosis comparing to for example TNFα ligand which has been 
investigated in detail a lot (Philipp et al., 2015). TRAIL-induced necroptosis can be activated under 
caspase-compromised conditions and enhanced by more stimuli, always by synergistic stimulation 
of TRAIL ligand with other factors for example acidic extracellular milieu or by blocking protein 
synthesis by e.g. homoharringtonine or by sirtinol-mediated blocking of histone deacetylation 
(Jouan-Lanhouet et al., 2012; Pal et al., 2013; Sosna et al., 2016). The basic mechanism of 
necroptosis proceeds similarly to TNFα-induced necroptosis (see chapter 1.1.2 Necroptosis). The 
necroptotic signalling triggered by TRAIL is also dependent on RIPK1 and RIPK3 kinases and 
phosphorylated MLKL-mediated permeabilisation of the cytoplasmic membrane (Jouan-Lanhouet 
et al., 2012). TRAIL-induced necroptosis is apparently negatively regulated by E3 ligase TRAF2, 
which in the complex with cIAP1/2 targets RIPK1 for proteosomal degradation (Karl et al., 2014).  
Interestingly, TRAF2 also suppresses TRAIL-induced apoptosis through targeting p18 subunit of 
activated caspase-8 for degradation. Apparently PARP-1 might also play a role in TRAIL-induced 
necroptosis. Jouan-Lanhouet and his colleagues showed that in acidic environment TRAIL-
induced necroptosis also involved RIPK1/RIPK3-dependent PARP-1 activation and depletion of 
ATP (Jouan-Lanhouet et al., 2012). However, PARP-1 participation in TRAIL-induced 
necroptosis might be just auxilliary as its inhibition or genetic ablation in embryonic MEF cells 
did not prevent TRAIL-mediated necroptosis (Sosna et al., 2016).  
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1.2.4.2 Other non-canonical TRAIL-induced signalling pathways 
    Whereas the induction of apoptosis is a default TRAIL-induced signalling in permissive cells, 
TRAIL can similarly to other members of TNF ligand family promote cell survival, proliferation, 
migration, cytokine secretion and immunomodulation and even invasion and metastasis (Karstedt 
et al., 2015; Karstedt et al., 2017). These non-canonical signalling pathways include activation of 
canonical NFκB signalling, MAPK kinases (p38, ERK1/2 and JNK) as well as activation of other 
kinases such as AKT, PKC or TAK-1. These non-canonical or auxiliary signalling pathways 
mainly negatively affect TRAIL-induced apoptosis and can also promote survival and migration 
of cancer cells as was recently documented for non-small cell lung cancer cells containing KRAS 
mutation, where the endogenous TRAIL induced cell migration by activating PI3K pathway. 
Interestingly these TRAIL-triggered pro-invasive behaviour was independent of the DR5 death 
domain but required the membrane proximal domain (MPD) (deMiguel et al., 2016; Lafont et al., 
2017). 
    The activation of NFκB pathway by TRAIL proceeds very similarly as for TNFα/TNFR1 
signalling (Fig. 1.10).  NFκB could be activated by TRAIL binding not only to DR4 or DR5 
receptor, but additionally also to DcR1 receptor with the truncated intracellular domain (Degli-
Esposti et al., 1997; Schneider et al., 1997). TRAIL-induced activation of non-canonical signalling 
mainly proceeds through the cytosolic complex II, but according to recently published data the 
membrane-associated complex I is at least partly involved in this signalling (Lalaoui et al., 2011). 
The core components, presented in both complexes, are among others, FADD, caspase-8, RIPK1 
and IKK complex. The essential players of non-cell death signalling are FADD, adaptor protein, 
which forms a scaffold for the formation of both complexes and caspase-8, which is involved in 
TRAIL-dependent gene activation and cytokine production (Tang et al., 2003; Kreuz et al., 2004; 
Varfolomeev et al., 2005; Henry et al., 2017). NFκB pathway is strongly activated in cancer cells 
resistant to TRAIL-induced apoptosis and can lead to their enhanced proliferation and 
migration/invasion thus promoting tumorigenesis (Hartwig et al., 2017). Interestingly it was found 
out that NFκB could mediate the upregulation of TRAIL receptors and recently it was published 
that in glioma cell lines, the inhibition of NFκB signalling attenuated their TRAIL-induced 
apoptosis (Liu et al. 2017). Likewise in TNFR1, ubiquitination by E3 ligases as cIAP1/2, HOIP or 
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LUBAC and de-ubiquitination by DUBs A20 or CYLD are very important regulatory events of 
TRAIL-induced activation of NFκB pathway (Fig. 1.10; Lafont et al., 2018). 
     The formation of mainly secondary cellular signalling complex II could in addition to NFkB 
TRAIL-induced non-canonical signalling lead to activation of MAPK kinases of ERK, JNK and 
p38 family. These kinases participate in such processes as inflammation, cell proliferation, 
apoptosis and differentiation. ERK is mostly associated with proliferation and growth factors. 
TRAIL-induced ERK activation is connected with its anti-apoptotic impact and in several reports 
was documented that the activation of ERK kinases can inhibit the processing of caspase-8 and 
Bid or in human melanoma cell lines can inhibit release of Smac/DIABLO from mitochondria. 
Suppressing activity of ERK kinases by specific inhibitors enhanced apoptosis of human breast 
cancer cells (Tran et al., 2001; Soderstrom et al., 2002; Zhang et al., 2003; Lee et al., 2006).  
     On the contrary, p38 and JNK are kinases triggered by stress factors and cytokines and can 
mediate differentiation and cell death. P38 kinase was shown to either enhance or supress cell 
death. It was published in HeLa cells that TRAIL-induced ROS production mediated activating of 
p38 signalling and subsequent cell death. Activity of p38 was essential for the proceeding of 
apoptosis, however other types of cancer as prostate cancer or breast carcinoma cells were shown 
to be sensitized to TRAIL induced apoptosis after chemical inhibition of p38 (Azijli et al., 2013).     
     JNK kinases are in mammals encoded by three genes: JNK1, JNK2 and JNK3 with several 
splice forms JNKs are activated as classical MAPK kinase in three step cooperative 
phosphorylation by MAPK3/MAPK2/MAP kinase. These stress kinases are involved in several 
cellular processes as proliferation, invasive migration, drug resistance and programmed cell death. 
In addition to apoptosis, JNKs were also shown to have a role in regulating of other types of 
programmed cell death such as necroptosis, ferroptosis, pyroptosis and autophagy like cell death 
(Tait et al., 2014; Abe et al., 2016; Xie et al., 2016; Dhanasekaran and Reddy, 2017). JNKs could 
be activated by death receptors as TNFR1, FasR or TRAIL receptors or by intrinsic stress signals 
via mitochondria (Dhanasekaran and Reddy, 2017). The phosphorylated JNK translocates to the 
nucleus where it by phosphorylation of the transcription factor c-Jun triggers formation of 
heterodimeric AP-1 transcription factor (Holler et al., 2000). In the pro-apoptotic branch of its 
activity, AP-1 is involved in the expression of several pro-apoptotic genes: TNF-α, Fas-L, TRAIL-
R2, Bak, Bax and Bim (Chen et al., 2010). JNKs can also phosphorylate other transcription factors 
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including JunD, ATF2/3, c-Myc or the most important p53 and p73, enhancing their stabilisation. 
Activated p53 itself enhances transcription of a number of pro-apoptotic genes including Bcl-2 
family memberes Bax, Puma and Noxa, death receptors FasR and DR5 and others (Davis et al., 
2000; Dhanasekaran and Reddy, 2017).  Modulation of the intrinsic apoptosis by JNKs relies in 
addition to the increased expression of pro-apoptotic Bcl-2 family proteins also on their JNKs-
mediated phosphorylation that affects their function and/or localization. Bax translocation to the 
mitochondria membrane and subsequent MOMP is increased when JNK phosphorylates Bax 
cytoplasmic anchor protein (Tsuruta et al., 2004). Bcl-2 family member Bim is phosphorylated in 
hepatocytes upon TRAIL treatment and this phosphorylation leads to the stabilisation of the 
protein and helps on its pro-apoptotic activity (Corazza et al., 2006). There is an evidence that JNK 
can contribute to promoting of apoptosis by direct phosphorylation of anti-apoptotic protein Bcl-
2, which suppresses its anti-apoptotic function (Yamamoto et al., 1999). Interestingly, activated 
JNK kinase could in addition to pro-apoptotic induce also anti-apoptotic signalling. Using RNA 
interference or specific JNK inhibitors in hepatocellular carcinoma cells surprisingly led to 
TRAIL-induced apoptosis (Mucha et al., 2009). There might be multiple reasons for this 
apparently anti-apoptotic effect of JNKs. One of them could be the kinetics of JNKs activation, as 
it was shown for TNFα-induced signalling where longer activation induced cell death whereas 
transient activation led to the cell survival.  Another reason might be different expression of JNK1 
splice variants as the activation of short isoform JNK1 is anti-apoptotic but its long isoforms 
enhances apoptosis in colorectal cancer cell lines (Ventura et al., 2006; Mahalingam et al., 2009). 
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Figure 1.10: TRAIL induced signalling and its regulation. TRAIL binding to its pro-death 
receptors induces formation of the membrane-bound complex I with a subsequent formation of the 
cytosolic complex II.  Both of these complexes can play a role in the activation of cell death 
signalling and/or pro-survival pathways. Multiple ubiquitination events play an important role in 
functional regulation of these complexes. Adapted from Lafont et al., 2018. 
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2 AIMS OF THE WORK 
 
     The main aim of this study was to expand the knowledge in the field of TRAIL-induced 
signalling and regulated cell death, especially in the context of cancer treatment.  This general aim, 
could be diversified into following goals: 
1. To answer the question whether there is a similar or distinct regulation of two pro-apoptotic 
TRAIL receptors DR4 and DR5 by analysing in detail the canonical and non-canonical 
signalling from our modified and enhanced TRAIL receptor-specific ligands in a model of 
colorectal and pancreatic cancer cells. 
2. To analyse TRAIL induced signalling in a model of human embryonic stem cells (hESC) and 
human-induced pluripotent stem cells (hiPSC). 
3. To analyse the sensitizing effect of Manumycin A itself or in combination with other 
sensitizers, mainly inhibitors of Bcl-2 proteins in TRAIL resistant colorectal cancer cell lines. 
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3 MATERIALS AND METHODS 
 
3.1 Bacterial strains, growth media and chemicals 
• TOP10               F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(araleu)7697 galU galK rpsL (StrR) endA1 nupG 
• Stbl3                  F-mcrB mrrhsdS20(rB-, mB-) recA13 supE44 ara- 
14 galK2 lacY1 proA2 rpsL20(StrR) xyl-5 λ-leumtl-1 
• BL21-AI™        F-ompT hsdSB (rB- mB-) gal dcm araB::T7RNAP-tetA 
     All bacterial strains were purchased from Invitrogen (Thermo Fisher). Escherichia coli strains 
TOP-10 and Stbl-3 were used for preparation of plasmid constructs and BL21-AI™ strain was 
used for the recombinant protein expression. 
     E.coli strains were grown in LB medium (LB Broth Miller, Amresco) with ampicillin (100 
ug/ml) (preparation of plasmids and recombinant proteins) or on LB agar plates with ampicillin 
(100 ug/ml) (transformation and sub-cloning). All other further unspecified chemicals were 
purchased from Sigma-Aldrich. 
3.2 DNA constructs and methodological approach used for their preparation  
 Restriction digestion and ligation 
     All restriction endonucleases were purchased from Fermentas (Thermo Fisher) and used 
according to the manufacturer protocol. Upon cleavage, the relevant DNA fragments were 
separated by agarose electrophoresis and purified from agarose gels by Zymoclean™ Gel DNA 
Recovery (Zymo Research). The subsequent ligation of digested vector and insert was performed 
using T4 DNA ligase and ½ of the ligation reaction was used for the transformation of bacteria 
TOP10 and Stbl3. 
 Polymerase chain reaction- PCR and DNA sequencing 
     Amplification of a target gene was carried out by Phusion High Fidelity DNA Polymerase 
(Finnzymes, now Thermo Fisher) and the resulted PCR product was cleaved with relevant 
enzyme(s) and cloned into a desired vector. For colony PCR screening was used DreamTaq Green 
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PCR Master Mix (2X) (Thermo Fisher). The set-up of both PCR reactions (Phusion and 
DreamTaq) followed their manufacturer’s instructions. For the verification of the amplified insert 
sequence were all PCR products cloned in relevant plasmids sequenced (SeqMe company) and the 
expression vectors without any mutation or deletion  were used in further experiments.  
 TRAIL ligand variants and reagents 
     We prepared several forms of  recombinant ligands containing in addition to the common 
bacteriophage trimerisation (TRI) motif  and the sequence coding for extracellular part of human 
TRAIL (amino acids 95-281) also the N-terminal either double- Twin Strep-tag (TST) or the His6 
tag. Both TST-TRI cassettes and receptor-specific TRAIL ligand variants were synthetized 
(GeneScript) and sub-cloned into modified pBSKII vector containing T7 promoter and an upstream 
sequence from the pET15b plasmid. TRAIL receptor-specific mutants were: DR4.02 
(G131R/R149I/S159R/N199R/K201H/S215D, 4C7 mutant; Reis et al., 2010), DR5.01 
(E195R/D269H; Van der Sloot et al., 2006) and mutant DR5.02 
(Y189N/R191K/E195R/H264R/I266L/D269H; Gasparian et al., 2009). Using this procedure we 
obtained several constructs: 
 
1. pBSKII-TST-TRI-TRAIL WT 
2. pBSKII-TST-TRI-TRAIL 4.2 
3. pBSKII-TST-TRI-TRAIL 5.1 
4. pBSKII-TST-TRI-TRAIL 5.2 
 
     His-tagged ligands were prepared using similar approach. All previous Strep-tagged constructs 
were digested and Twin-Strep-tag was cut out. Then His tag was inserted in frame with 
trimerisation motif. We obtained following constructs: 
   
1. pBSKII -His-TRI-TRAIL WT 
2. pBSKII-His-TRI-TRAIL 4.2 
3. pBSKII-His-TRI-TRAIL 5.1 
4. pBSKII-His-TRI-TRAIL 5.2 
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 The list of vectors, primers and shRNA used in experimental work 
Vectors: 
• pUC57-TST-TRI 
The original plasmid ordered from GeneScript company, containing Twin-Strep-tag in-frame 
with bacteriophage trimerisation (TRI) motif. 
• pBSKII + human TRAIL wild type 
• pUC57-DR4.2 
The original plasmid with the sequence for mutant TRAIL ligand specific to DR4 receptor. 
Ordered from GeneScript. 
• pUC57-DR5.1 
The original plasmid with the sequence for mutant TRAIL ligand specific to DR5 receptor. 
Ordered from GeneScript 
• pUC57-DR5.2 
The original plasmid with the sequence for mutant TRAIL ligand specific to DR5 receptor. 
Ordered from GeneScript. 
• modified pBSKII+ containing T7 promoter and upstream region from pET15b 
Used for expression of TRAIL constructs in bacteria. 
• psPAX2 (Addgene, #12260) 
Lentiviral packaging plasmid, used for the producing of lentiviruses in HEK293T/17 cells. 
• pMD2.G (Addgene, #12259) 
Lentiviral packaging plasmid, used for the producing of lentiviruses in HEK293T/17 cells. 
• pLKO empty (Addgene, #8453) 
Used for expression of shRNA of target gene in mammalian cells. Serves also as a control for 
non-specific effect of DNA construct in the cells. 
• pLKO non-targeting shRNA control (#109012) 
Used as a control to pLKO with target shRNA. 
shRNA: 
• shDR4_#1 TRCN0000005934 
• shDR4_#2 TRCN0000005935 
• shDR5_#1 TRCN0000005929 
• shDR5_#4 TRCN0000005932 
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• shDR5_#5 TRCN0000005933 
• shFLIP_#1  TRCN0000007229 
• shFLIP_#2 TRCN0000007230 
• shMcl-1_#1 TRCN0000005514 
• shMcl-1_#2 TRCN0000005515 
• shMcl-1_#3 TRCN0000005516 
• shMcl-1_#4 TRCN0000005517 
• shMcl-1_#5 TRCN0000005518 
• shMcl-1_#6 TRCN0000005519 
Primers: 
• Strep-TRI-TRAIL-U (5’Xho) CGCTCGAGACCTCTGAGGAAACCATTTC 
  
• StrepTRI-TRAIL-L (3’BamHI) CGGGATCCTTAGCCAACTAAAAAGGCCC 
     
 
 Transformation of chemically competent E.coli strain  
     50 ul of chemically competent TOP10 or Stbl-3 bacteria strain were transformed by 5 ul of the 
ligation reaction or 0.5 ug of plasmid DNA. After 30 min of incubation on ice, bacterial suspension 
was transferred to 42 °C (1 min) to induce heat-shock. Then LB medium (500 ul) was added and 
bacteria were cultivated at 37 °C, 250 rpm for 30 min. After pelleting (15 s, 13000 rcf) were 
bacteria ressuspended in 100 ul of LB and seeded onto agar plates containing proper selection 
antibiotic.  
 Plasmid preparations using alkaline lysis and column-based systems 
     For the plasmid alkaline lysis minipreps, the bacterial cultures (1 ml) grown for 12-15 hrs, 250 
rpm at 37°C were centrifuged (15-30 s, 13000 rcf) and bacterial pellets were resuspended in 100 
ul of the Sol I (50 mM glucose, 25 mM Tris.HCl pH 8.0, 10 mM EDTA pH 8.0). The suspensions 
were lysed with 200ul of the Sol II (0.2 M NaOH, 1% SDS) and then neutralized using 150 ul of 
Sol III (5 M sodium acetate, 12 % acetic acid). Heterogenic suspensions containing bacterial 
chromosomal DNA, lipids and proteins were pelleted 10 min, 13000 rcf. Nucleic acids (plasmid 
DNA and bacterial RNA) from the supernatants were purified at first by 1 ml of 100 % ethanol 
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and then 0.5 ml of 70 % ethanol. Plasmid DNAs were diluted in TE buffer (10 mM Tris-HCl pH 
8.5, 0.1 mM EDTA) with RNAase (10 ug/ml) and stored at -20°C. 
     Plasmid miniprep using Zyppy Plasmid Miniprep Kit (Zymo Research) was performed 
according to the manufacturer protocol. DNA was diluted in TE buffer or in water and stored at -
20°C. For isolating of bigger amount of DNA we used Geneaid Plasmid Midi Kit (Geneaid 
Biotech). Plasmid DNA was isolated according to the manufacturer protocol. DNA was diluted in 
TE buffer or in water and stored at -20°C.  
3.3 Expression of recombinant proteins in E.coli and purification methods  
     For the expression of recombinant TRAIL ligands was used bacterial strain BL21-AI E.coli 
(Thermo Fisher), which contains a chromosomal insertion of the gene encoding T7 RNA 
polymerase into  araB locus of the araBAD operon, placing regulation of T7 RNA polymerase 
gene under the control of araBAD promoter. Expression of mRNA from araBAD operon was 
regulated by use of L-arabinose in the mid-log phase of growth of bacterial culture. 
     Transformed BL21-AI E.coli bacteria with recombinant expression plasmid were inoculated to 
50 ml of LB media with ampicillin (100ng/ml) and culture was grown O/N at 37 °C, 250 rpm. This 
starting culture was used for the inoculation of 1l of LB media with ampicillin (100ng/ml) and 
cells were grown till they reached the early-mid log phase of cell growth (OD600 = 0.5) at 37 °C, 
250 rpm. The culture was then cooled down to 25°C and for the induction of TRAIL expression 
was used 0.2%w/v L-arabinose. The culture was grown other 4-6 hrs at 25°C, 200 rpm, then 
centrifuged and pellets were further lysed and purified.   
 
 Purification protocol for Twin Strep-tagged TRAIL ligands 
Lysis buffer: 
20mM Hepes.Na, pH 7.9 
300mM NaCl 
0.1% Tween-20 
5% glycerol 
1x Complete protease inihibitor (Roche) 
1mM mercaptoethanol 
Washing buffer: 
100mM Tris-HCl pH 8.0 
150 mM NaCl 
1 mM EDTA 
0.1% Tween-20 
5% glycerol 
1mM mercaptoethanol 
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Elution buffer: 
100mM Tris-HCl pH 8.0 
150 mM NaCl 
1 mM EDTA 
2mM biotin (Sigma) 
1x Complete protease inihibitor (Roche) 
1mM mercaptoethanol 
 
 
 
 
 
Figure 3.1: Scheme of Strep-tag and Twin Strep-tag purification system (IBA life sciences). 
System is based on the interaction of biotin with streptavidin, where recombinant peptide analogue 
of biotin (Strep-tag) has very high binding affinity to Streptactin (analogue of streptavidin). For 
purification of protein complexes Twin-Strep tag (TST) with two Strep-tags in row was used.   
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     Bacterial cells were resuspended in the lysis buffer and then sonicated using 5 pulses each 
for 10 seconds (Ultrasonic homogenizer, Cole-Parmer). Sonicated lysate was centrifuged by 
ultracentrifugation (80,000x g, 4°C, 1h, Beckman Coulter) and supernatant was loaded on 5ml 
Gravity flow Strep-Tactin Sepharose column (IBA life sciences, Fig. 3.1). Purification of Twin-
Strep tagged TRAIL ligands was performed according to the general protocol for Strep-tag 
recombinant protein purification (Schmidt and Skerra, 2007) and manufacturer instructions 
(IBA life sciences). Briefly, the matrix (Streptactin Sepharose) with bound TST-TRI-TRAIL 
was 5x times washed with 1 CV (column bed volume) of the washing buffer. Recombinant 
TRAIL was eluted in several fractions (6-10) with 0.5 CV of the elution buffer containing 
biotin. Each washing and elution fraction was collected and 5ul was taken aside for SDS-PAGE 
electrophoresis and Coomassie blue staining (more in part 3.8 SDS-PAGE electrophoresis and 
3.9 CBB-R250 staining). Concentration of the purified proteins was determined using the 
extinction coefficient and Nanodrop. Aliquotes were diluted approx. to 1 mg/ml and stored at -
80°C.   
 
 Purification protocol for His-tagged TRAIL ligands 
 
Washing buffer 1: 
20 mM Hepes.Na, pH 7.9 
300 mM NaCl 
0.05% Tween-20 
2% glycerol 
1mM mercaptoethanol 
 
Washing buffer 2: 
20 mM Hepes.Na, pH 7.9 
300 mM NaCl 
0.05% Tween-20 
2% glycerol 
1mM mercaptoethanol 
5mM imidazole 
 
 
 
Elution buffer 
20 mM Hepes.Na, pH 7.9 
300 mM NaCl 
0.05% Tween-20 
2% glycerol 
1mM mercaptoethanol 
100mM imidazole 
 
Dialysis buffer: 
20 mM Hepes.Na, pH 7.4 
50 mM NaCl 
0.01% Tween-20 
10 g sucrose 
38 mg DTT 
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     His-tagged proteins were purified in a similar way as Strep-tagged. Purification was 
performed according to the general instructions of manufacturer (Clontech). Supernatant of 
sonicated and centrifuged bacterial lysate was mixed with equilibrated TALON resin 
(Clontech) and gently rotated at 4°C for 30 minutes. Then the resin was washed twice with the 
washing buffer w/o and w/ low concentration of imidazole. The slurry of resin was resuspended 
in washing buffer 2, poured into TALON column (Clontech) and washed with 10 CV of 
washing buffer 2. Proteins were eluted with 5 CV of elution buffer and protein content in 0.5 
ml fractions (0.5 ml/6-10 fractions) was quantified by Bradford method (Bradford, 1976). Only 
fractions with highest protein concentration were collected and used in further purifications 
steps. For removing imidazole and other salts, the pooled fractions were dialyzed O/N against 
1l of dialysis buffer in pre-treated dialysis tubing (cut-off 10K) and analysed by SDS-PAGE 
electrophoresis and Coomassie blue staining (more in part 3.8 SDS-PAGE electrophoresis and 
3.9 Coomassie blue staining). Concentration of the purified proteins was determined using the 
extinction coefficient and Nanodrop photometer, aliquotes were diluted approx. to 1 mg/ml and 
stored in -80°C.   
3.4 Manipulation with mammalian cell lines 
Human cell lines and media: 
• HT-29- human colorectal adenocarcinoma cell line (HTB-38) 
• PANC-1- human pancreatic adenocarcinoma cell line (CRL-1469) 
• RKO- human colorectal adenocarcinoma cell line (CRL-2577) 
• SW620- human colorectal adenocarcinoma cell line (CCL-227) 
• HEK 293T/17- human kidney epithelial cells (CRL-11268) 
• Ramos- B-cell lymphoma cell line (CRL-1596) 
• Jurkat- T-cell leukemia cell line (TIB-152) 
• hESC (CCTL 12 and CCTL 14)- human embryonic cells (Dolezalova et al., 2012) 
• hiPSC- human induced pluripotent stem cells (Armstrong et al., 2010) 
     Human colorectal adenocarcinoma cell lines HT-29, RKO and SW-620, human pancreatic 
adenocarcinoma cell lines PANC-1 and human kidney epithelial cells HEK 293T/17 were 
obtained from the ATCC. B-cell lymphoma cell line Ramos and the acute T-cell leukemia cell 
line Jurkat were kindly provided by Vaclav Horejsi (Simova et al., 2008) and were originally 
also obtained from ATCC.  
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     For the experiments in part Results 4.2 were used hESC lines (CCTL 12 and CCTL 14) 
between passages 25-80 and hiPSC cell line (clone 4) between passages 50-80. Colonies of 
both cell lines were co-cultivated with mitotically inactivated mouse embryonic fibroblasts 
(MEFs) as described in Barta et al., 2010 or grown on extracellular MEF-derived matrix (ECM). 
Cultivation on ECM required MEF-conditioned hESC medium which was prepared as 
described in Vinarsky et al., 2013. 
     All unspecified media and cell culture additives were purchased from Sigma. Cells were 
cultured in DMEM (HT-29, PANC-1, RKO, SW-620, HEK 293T/17) or in RPMI (Jurkat, 
Ramos) supplemented with v/v 10% FCS (Life Technologies), L-glutamine and antibiotics. In 
the case of PANC-1, non-essential amino acids (Life Technologies) were added to the medium. 
Cells were kept in a humidified incubator at 20% oxygen, 5% CO2 and 37°C.  
3.5 Preparation of recombinant lentiviruses by calcium phosphate 
transfection and lenti-viral transduction of target cells 
      For the production of recombinant lentiviruses we used HEK 293T/17 cells, which 
constitutively express the simian virus 40 large T antigen and are easily transfectable with 
plasmid DNA. Day before transfection HEK293/T17 cells were seeded at 20-30% of 
confluency and 1 hr before the transfection, the cultivation medium was changed for a fresh 
one in addition containing 25µM chloroquine (inhibitor of lysosomal degradation of plasmid 
DNA). 
     Master mix containing 500 ul of 0.25M calcium chloride and two packaging plasmids 
psPAX2 (Addgene, #12260) and pMD2.G (Addgene, #12259) altogether with our target 
plasmid (e.g. pLKO1 expressing specific shRNA) was pipetted into eppendorf tubes and then 
500 ul of 2xBBS solution pH 6.9 (50mM BES, 280mM NaCl, 1.5mM Na2HPO4) was added in 
a dropwise manner. After 15 minutes was mastermix pipetted on the surface of petri dish. Cells 
were incubated in a special conditions with 3% of CO2 and 37°C. After 5-6 hrs were crystals of 
calcium salt washed away with PBS and fresh media was added. The medium containing 
lentiviral particles was harvested 36 to 48 hrs post-transfection, and the viral particules were 
precipitated using PEG-it (System Biosciences) according to manufacturer protocol. Target 
cells were transduced with viruses at multiplicity of infection MOI 5-10 and selected for 
puromycine resistance (2 µg/ml, Invivogen). 
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3.6 Affinity purification of protein complex DISC 
 
DISC lysis buffer: 
20 mM Tris-HCl, pH 7.5 
150 mM NaCl 
1% Tritone X-100 
10% glycerol 
1x Complete protease inhibitor (Roche) 
1 mM EDTA 
1mM sodium orthovanadate 
10mM NaF    
 
     Cells grown to approximately 80% confluence were rapidly cooled by the media exchange 
for an ice-cold one and then incubated on ice for 20 min (to prevent internalization of the 
receptors). Twin-Strep-tag labelled TRAIL ligand variants (TST-TRI-TRAIL) were added to 
the concentration of 1 µg/ml for 15 min, then the cold medium containing TRAIL was replaced 
with the 37°C warm one without TRAIL, and the cells were incubated at 37°C for specified 
time periods. At selected time points, the cells were washed with ice-cold PBS and the cell 
pellets were lysed in ice-cold DISC lysis buffer supplemented with inhibitors of proteases 
(Complete, Roche) and phosphatases (10 mM NaF and 1 mM Na3VO4). Lysates were adjusted 
to the same protein concentration and the same amount of protein (2 mg) was incubated/gently 
rotated with Streptactin beads (IBA) overnight at 4°C and then washed 3-4 times with 1 volume 
of ice-cold lysis buffer. The proteins bound to Streptactin beads were directly eluted with 2 x 
Laemmli sample buffer (95°C, 5 min) and analysed by Western blotting. 
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3.7 Preparation of protein lysates 
      Cells were lysed using SDS-based lysis buffer (2x Laemmli buffer: 50mM Tris-HCl pH 6.8, 
20% glycerol, 4% SDS) and samples were subjected to SDS-PAGE.   
 
Sample buffer 2x: 
50mM Tris-HCl pH 6.8 
20% glycerol 
4% SDS 
200mM DTT 
0.05% w/v  Bromphenol blue 
 
     Cells were washed twice with cold PBS. Then lysis buffer was added, cells were harvested 
by scraping and incubated at room temperature, sonicated (4 x 10s at 4 micron amplitude with 
15 s cooling intervals, Ultrasonic homogenizer, Cole-Parmer) and centrifuged (10 min, 13 000 
rcf, 4°C). Protein concentration in cleared lysates was determined by BCA assay (Thermo 
Fisher) and the samples with adjusted equal protein concentration were boiled with the equal 
volume of 2x Laemmli sample buffer and then subjected to SDS-PAGE electrophoresis. 
3.8 SDS-PAGE electrophoresis and Western blotting 
Chemicals and materials: 
• Separating gel in final concentration: different percentage of the final acrylamide: 
bisacrylamide (Biorad) concentration according to the molecular weight of protein of 
interest (10-30 kDa protein- 15%, 30-70 kDa- 12%, 70-100 kDa- 10%) (Biorad), 0.1% 
w/v SDS, 0.1% w/v ammonium persulfate, 375mM Tris pH 8.8, 0.01% TEMED. 
• Stacking gel in final concentration: 5% acrylamide-bisacrylamide (Biorad), 0.1% w/v 
SDS, 0.1% w/v ammonium persulfate, 125mM Tris pH 6.8, 0.01% TEMED. 
• PageRuler™ Prestained Protein Ladder, 10 to 180 kDa (Thermo Fisher)  
• 1x Running buffer: 200mM glycine, 25mM Tris-base, 0.1% w/v SDS 
• 1x Blotting buffer: 200mM glycine, 25mM Tris-base, 20% methanol  
• Blotting membrane- Amersham Protran Premium 0.45 µm NC (GE Healthcare) 
• Washing buffer: PBS, 0.05% Tween-20 
• Ponceau S solution: 0.1 % (w/v) in 5% acetic acid 
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• Blocking buffer: 5% w/v milk (Sigma) or 2% w/v bovine serum albumin (Sigma) in 
Washing buffer (PBS/Tween-20) 
• 10% w/v sodium azide  
• ECL1 soultion (home-made): 2.5mM luminol (5-amino-2,3-dihydro-1,4-ftalazindion) 
in 100 mM Tris-HCl pH 8.8 
• ECL2 solution (home-made): 5.4 mM H2O2 in 100mM Tris-HCl pH 8.8 
• Medical X-ray Blue / MXBE Film- Carestream® Kodak® BioMax® XAR Film 
(Sigma) 
• Pierce ECL Western Blotting Substrate (Thermo Fisher) 
• Western Bright ECL (Advansta) 
• SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher) 
 
     SDS-PAGE electrophoresis and Western blotting were performed according to standard 
protocols (Kurien and Scofield, 2015). The same amount of protein samples were together with 
the protein standards loaded on polyacrylamide gels. After SDS electrophoresis the gel was 
either stained with Coomassie Brilliant Blue R250 or the proteins were further transferred onto 
a nitrocellulose membrane using semi-dry Western blotting. The effectivity of the protein 
transfer was examined by Ponceau S staining and membrane was then blocked 30 min-1h with 
blocking buffer (see Chemicals and Materials). The proteins were detected using immuno-
staining method with primary antibodies specific to the protein of interest (O/N, 4 °C) and 
secondary antibodies conjugated with horseradish peroxidase (1h, RT). The protein-antibody 
complexes were visualized by ECL or Femto solution and luminescent signal was revealed by 
Medical X-ray Blue films or by Western blot imaging system from Azure Biosystems. 
3.9 Coomassie Brilliant Blue staining 
• Gel staining buffer: 10% w/v Coomassie Brilliant Blue R-250, 50% methanol, 10% 
acetic acid 
• Gel de-staining buffer: 40% methanol, 10% acetic acid 
 
     After SDS electrophoresis the gel was stained using gel staining buffer for 1h in RT, then 
was trasferred to gel de-staining buffer, where the backround colour of gel was washed out. 
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3.10 The list of antibodies used for immuno-detection 
If not stated otherwise, antibodies were obtained from Cell Signaling  
Primary antibodies: 
• anti-caspase-10 (9752) 
• anti-caspase-9 (9508) 
• anti-caspase-8 1C12 (9746) 
• anti-caspase-3 cleaved (9661) 
• anti-Bid (2002) 
• anti-IκB-α (4814) 
• anti-phospho IκB-α (2859, Ser32) 
• anti-NF-κB p65 (4764) 
• anti-phospho NF-κB (3033, Ser536) 
• anti-phospho SAPK/JNK (9255S, Thr183/Tyr185) 
• anti-p38/MAPK (9212) 
• anti-phospho p38/MAPK (9211S, Thr180/Tyr182) 
• anti-phospho MLKL (14516, Thr357/Ser358) 
• anti-PARP cleaved (9541)  
• anti-XIAP (2042) 
• anti-caspase-3 (804-305-C100, Enzo Life Sciences) 
• anti-FLIP (NF6, ALX-804-428, Enzo Life Sciences) 
• anti-FLIP (7F10, ALX-408-961, Enzo Life Sciences) 
• anti-DR4 (8414, Abcam) 
• anti-MLKL (184718, Abcam) 
• anti-DR5 (D3938, Sigma-Aldrich) 
• anti-FADD (610400,  Becton Dickenson) 
• anti-RIP1 (610458, Becton Dickenson) 
• anti-SAPK/JNK (sc-571, Santa Cruz) 
• anti-Mcl-1 (sc-819, Santa Cruz) 
• anti-actin (1615, Santa Cruz) 
• anti-α-tubulin (TU-01, Exbio) 
• anti-RIP3 (7604, MAB) 
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Secondary antibodies: 
• GAM-Px- goat anti-mouse secondary antibody, conjugated with horseradish peroxidase 
(115-035-205, Jackson Immuno Research Laboratories) 
• GAR-Px- goat anti-rabbit secondary antibody, conjugated with horseradish peroxidase 
(111-035-144, Jackson Immuno Research Laboratories) 
• RAG-Px- rabbit anti-goat secondary antibody, conjugated with horseradish peroxidase 
(305-035-003, Jackson Immuno Research Laboratories) 
3.11 Flow cytometry analysis  
     All flow cytometry analyses were run using LSRII and BD LSRFortessa instruments 
(Becton Dickenson). For all flow cytometry assays, the cells were seeded in 12 or 24 well plates 
and harvested at 80% confluency. Apoptosis was induced using human recombinant TRAIL 
ligand variants (TST-TRI-TRAIL WT, 4.2, 5.1, 5.2), His-TRAIL WT (Apronex) either alone 
or in combination with homoharringtonine (H0635, Sigma-Aldrich) or ABT-737 (S1102, 
Selleck Chemicals). TRAIL-mediated necroptosis was induced in cancer cells pre-treated with 
the IAP inhibitor birinapant (S7015) (Selleck Chemicals) and pan-caspase inhibitor Z-VAD-
FMK (ALX-260-020-M005, Enzo Life Sciences) or Z-IETD-FMK (550380, Becton 
Dickenson). Necroptosis inhibitors necrostatin-1 (S8037) and necrosulfonamide (5025) were 
purchased from Selleck Chemicals and from Tocris, respectively.  
 
 Assessment of apoptosis - Annexin V binding assay  
    TRAIL-treated and control cells were harvested by trypsinisation, washed with ice-cold PBS, 
then re-suspended in the Annexin-binding buffer (Apronex) and incubated on ice with Annexin 
V-FITC (Apronex) at the final concentration of 2 µg/ml for 20 min. Prior flow cytometry 
measurement Hoechst 33258 was added to the final concentration of 0.5 µg/ml. The 
experiments in Results 4.2 part were done according to the methods in Vinarsky et al., 2013. 
 
 Analysis of death receptor cell surface expression  
Cells were harvested by trypsinisation, then washed with ice-cold PBS, and re-
suspended in PBS containing 0.2 % gelatine and 0.1 % sodium azide (PBS-GA). The samples 
were incubated on ice with the primary antibodies against DR4 (10-403, EXBIO) and DR5 (11-
461, EXBIO) receptors at the final concentration 10 µg/ml for 30 min. After incubation, cells 
were washed twice with ice-cold PBS-GA and incubated with the secondary goat anti-mouse 
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IgG1 conjugated with phycoerythrin (final concentration 4 µg/ml; 1070-09, Southern Biotech) 
on ice for 30 min. Cells were then washed twice with cold PBS-GA, re-suspended in PBS-GA 
with Hoechst 33258 (0.5 µg/ml) and analysed by flow cytometry. 
 
 Assessment of necroptosis 
     For quantification of necroptosis, cells were harvested with accutase, washed with HBSS 
with 5uM EDTA and re-suspended in HBSS/EDTA. Propidium iodide was added to the final 
concentration of 2 µg/ml, and cells were analysed by flow cytometry. 
 
 Detection of mitochondrial ROS 
     Harvested cells were pelleted (300 rcf, 5 min) and washed with PBS. Then MitoSOX™ 
Red Mitochondrial Superoxide Indicator (Thermo Fisher) was added in the final concentration 
5µM, following the manufacturer protocol, and cells were analysed by flow cytometry. 
3.12 Real-time quantitative PCR 
     Total cellular RNA was isolated using RNA Blue (Top-Bio) according to the manufacturer’s 
instructions. Isolated RNA was diluted in RNAase free water and its concentration was 
quantified by Nanodrop Spectrophotometer (Thermo Fisher). The equal amount of RNA (1-2 
ug) was reverse transcripted using RevertAid RT Reverse Transcription Kit (Thermo Fisher) 
following manufacturer’s protocol. cDNA was 5x diluted in RNase free water. 
  Diluted cDNA was together with relevant primer pair (see below) amplified using Light 
Cycler 480 SYBR Green I Master kit (Roche) in Light Cycler 480 (Roche) according to the 
manufacturer’s instructions. To calculate the relative amount of mRNA was used formula: 
 
relative concentration of RNA = 2Cp (control)-Cp (sample) 
 
All RT-qPCR analyses were normalized to the expression of selected house-keeping genes 
(GAPDH, SDH, RPL37A, β-actin). 
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 The list of primers used in real-time PCR: 
 
GAPDH fwd AATTGAGCCCGCAGCCTCCC 
GAPDH rev TGAGCGATGTGGCTCGGCTG 
βActin fwd GGCATCCTCACCCTGAAGTA 
βActin rev AGGTGTGGTGCCAGATTTTC 
RPL37A fwd ATTGAAATCAGCCAGCACGC 
RPL37A rev AGGAACCACAGTGCCAGATCC  
SDH fwd AGATTGGCACCTAGTGGCTG 
SDH rev ACAAAGGTAAGTGCCACGCT 
cIAP1 fwd CAATCAAGGGTACAGTTCGTACA 
cIAP1 rev GACGATGTTTTGGTTCTTCTTCA 
cIAP2 fwd TTGTTGAACACTTGAAGCCATC 
cIAP2 rev ACCAAAGCAGACTAGAACATGAA 
DR4 fwd AACATCGTGCCCTTTGACTC 
DR4 rev TACCAGCTCTGACCACATCG 
DR5 fwd CCAGCAAATGAAGGTGATCC 
DR5 rev GCACCAAGTCTGCAAAGTCA 
 
3.13 Statistical analysis 
     Statistical analysis was carried out using the GraphPad Prism 6 software. Experiments were 
performed in at least three biological replicates, data are presented as mean values ± SEM, 
statistical significance was evaluated using ANOVA with differences at p ≤ 0.05 considered 
significant. 
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4 RESULTS 
 
4.1 TRAIL induces apoptosis but not necroptosis in colorectal and 
pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor 
Summary 
     Human TRAIL is a cytokine that can via engagement of its two pro-apoptotic receptors 
TRAIL-R1 (DR4) and TRAIL-R2 (DR5) trigger in addition to apoptosis a number of other 
signalling pathways such as necroptosis, canonical NF-κB signalling or can activate stress 
kinases. Though both of these signalling receptors are ubiquitously expressed, their relative 
participation in TRAIL-induced signalling is still largely unknown. To analyse TRAIL 
receptor-specific signalling, we prepared Strep-tagged, trimerised variants of recombinant 
human TRAIL with high affinity for either DR4 or DR5 receptor. Using these receptor-specific 
ligands, we examined the contribution of individual pro-apoptotic receptors to TRAIL-induced 
signalling pathways. We found that in TRAIL-resistant colorectal HT-29 cells but not in 
pancreatic PANC-1 cancer cells, DISC formation and initial caspase-8 processing proceeds 
comparably via both DR4- and DR5-activated signalling. TRAIL-induced apoptosis, enhanced 
by the inhibitor of the Bcl-2 family ABT-737, or by the translation inhibitor homoharringtonine, 
proceeded in both cell lines predominantly via DR5 receptor. ShRNA-mediated downregulation 
of DR4 and DR5 receptor in HT-29 cells also pointed to a stronger contribution of DR5 in 
TRAIL-induced apoptosis. In contrast to apoptosis, necroptotic signalling was activated 
similarly by both DR4- or DR5-specific ligands. Activation of auxiliary signalling pathways 
involving NF-κB or stress kinases proceeded under apoptotic conditions mainly in a DR5-
dependent manner, while these signalling pathways were during necroptosis similarly activated 
by either of these ligands. Our study provides the first systematic insight into DR4−/DR5-
specific signalling in colorectal and pancreatic cancer cells. 
 
Declaration of honour 
      This is a first-author paper work, where author contributed by most of the experiments with 
exception of following: cloning of vectors for receptor specific TRAIL ligands was done by 
Martin Peterka for TST-TRI-TRAIL variants and Jan Švadlenka for His-TRI-TRAIL ligands, 
qPCR in Fig. 4.14 was done by Jan Švadlenka. Simona Benešová and Marie Ksandrová 
partially contributed with Western blots in Fig. 4.6 A-B and in Fig. 4.13 A. Jan Švadlenka 
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partially contributed to Western blots showed in Fig. 4.8 C. Data in Fig. 4.14 were not inlcuded 
in the published paper Nahacka et al., 2017.  
 
4.1.1 Preparation of TRAIL receptor-specific ligands 
     For the detail analysis of TRAIL receptor-specific signalling in cancer cells, we designed 
and prepared recombinant TRAIL ligands specifically binding to either DR4 or DR5 receptor 
(Fig. 4.1, see also Materials and Methods: TRAIL ligand variants and reagents). Soluble 
recombinant human TRAIL contains the extracellular region of human TRAIL encompasing 
amino acids 95-281. To increase its effectivity and to mimic its trimeric formation we 
introduced T4 phage trimerisation/stabilisation (TRI) motif to the N-terminal sequence of the 
recombinant ligand. Furthermore, Twin Strep-tag (TST) sequence was included at the N-
terminus allowing both its purification from the E.coli lysates as well as isolation of specific 
TRAIL receptor DISCs. DR4 (marked TST-TRI-TRAIL 4.2) and DR5 specific ligands (marked 
TST-TRI-TRAIL 5.1 and TST-TRI-TRAIL 5.2) were prepared by gene synthesis introducing 
specific mutations into sequence of human WT TRAIL ligand (marked TST-TRI-TRAIL WT) 
as showed in Fig. 4.1. For better understanding, TRAIL ligand variants will be in next pages 
mentioned in shorter name as TST-TRAIL WT/4.2/5.1/5.2. 
     Recombinant ligands were expressed in E.coli BL21-AI and purified using Streptactin 
Sepharose system to approx. 95% purity (assessed from SDS-PAGE, data not shown). 
Biological activity and selectivity of these ligands was assessed using two hematopoietic cell 
lines: predominantly DR4-signalling Ramos cells (Burkitt lymphoma cells) and DR5-signalling 
Jurkat cells (T cell leukemia cells). Fig. 4.2 A shows the cell surface expression of both TRAIL 
receptors and Western blotting analysis in Fig.4.2 B reveals their total cellular levels. Though 
Ramos cells expressed both receptors, DR4 as well as DR5, it has been documented that they 
signal just via DR4 receptor (Sung et al., 2009). Jurkat cell line had almost none expression of 
DR4 receptor and expressed uniquely DR5 both at the cellular and cell surface levels.   
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Figure 4.1: Graphical scheme of recombinant DR4- and DR5-specific TST-TRI TRAIL 
ligands.  
              
Figure 4.2: Analysis of TRAIL receptors DR4 and DR5 expression in Ramos and Jurkat 
cells. Cell surface expression of DR4 and DR5 receptor in Jurkat and Ramos cell lines was 
evaluated by flow cytometry (A). The relative signal is calculated with respect to the control 
cells stained only with the secondary antibody. Total expression was assessed by Western 
blotting (B). Data in A were analysed by ANOVA using GraphPad Prism 6 software and are 
presented as mean values ± SEM with differences at p ≤ 0.05 considered as significant. 
Presented data A-B are representative of at least three biological replicates.   
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Figure 4.3: Assesment of the physiological activity and selectivity of TRAIL receptor-
specific ligands. Jurkat and Ramos cells were treated with 5, 10, 25, 50 and 100 ng/ml of TST-
TRAIL WT, 4.2, 5.1, 5.2 for 3hrs (Jurkat) or 4 hrs (Ramos) (A-B). Apoptotic cells were stained 
with annexin V-FITC and quantified by flow cytometry. Data are presented as mean values ± 
SEM. Presented data are representative of at least three biological replicates. 
A 
B 
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     The apoptosis assays using the recombinant TST-TRAIL WT and TRAIL receptor-specific 
mutants in Ramos and Jurkat cells confirmed selectivity and activity of all purified ligands (Fig. 
4.3). In agreement with the previous results, Jurkat cell line (Fig. 4.3 A) showed almost none 
response to DR4-specific ligand, while both DR5-specific ligands were very effective in 
inducing dose-dependent apoptosis of Jurkat cells (Fig. 4.3 A) (Jang et al., 2003). Interestingly, 
the ligand 5.2 excelled in inducing Jurkat cells apoptosis and at its concentration of 5 ng/ml 
induced death of over 80% of Jurkat cells  while TST-TRAIL WT at the same concentration 
induced apoptosis of about 50% of these cells and reached “killing plateau” of 80% of 
dead/dying cells only at the concentration of 50 ng/ml. DR4-specific ligand TST-TRAIL 4.2 
was as documented in Fig. 4.3 B about twice more efficient than TST-TRAIL WT, while DR5-
selective ligands were fairly ineffective even at the highest concentrations. It is inevitable to 
mention here, that during the initial steps we also prepared His-tagged TRAIL ligands WT and 
specific to DR4 and DR5 receptor (see Materials and Methods, part 3.2). His-tagged TRAIL 
WT was in several cell lines more efficient in inducing of cell death than Strep-tagged TRAIL 
WT (similarly His-tagged TRAIL is more effective comparing to leucine zipper TRAIL, see 
Engels et al., 2005), but when testing the selectivity of His-tagged DR4/5 specific ligands, these 
turned out to profoundly less selective than TST-tagged TRAIL (data not shown).  
4.1.2 DR5 receptor-specific TRAIL ligands effectively induce apoptosis in colorectal and 
pancreatic cancer cells 
     Among the most studied types of tumours in the field of TRAIL-induced signalling belong 
those of colorectal and pancreatic origin. For the experiments addressing efficacy of our TRAIL 
receptor-specific ligands we selected widely used HT-29 colon colorectal adenocarcinoma cell 
line and PANC-1- pancreatic epitheloid carcinoma cells. Initially we determined cellular levels 
as well as relative cell surface expression of both pro-apoptotic TRAIL receptors DR4 and DR5 
(Fig. 4.4 A-B). DR4 total protein levels are higher in PANC-1 cells, but its cell surface 
expression is  comparable with the expression on HT-29 cells, which express largely less of 
total cellular DR4. DR5 cell surface expression, however reflects its total cellular expression 
and seems to be at least twice higher in HT-29 cells than in PANC-1 cells.  As both of these 
cell lines are being resistant to TRAIL-induced apoptosis (Fig. 4.7 B-C), its effective induction 
requires using a sensitizer. For this purpose we used homoharringtonine (HHT), an inhibitor of 
translation and FDA approved anti-CLL drug, which was shown to downregulate mainly FLIP-
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1 and Mcl-1 anti-apoptotic proteins, and BH3 analogue ABT-737, that inhibits Bcl-2, Bcl-Xl 
and Bcl-w (Beranova et al., 2013; Konopleva et al., 2006).  
 
 
 
Figure 4.4: Cell surface and total protein expression of DR4 and DR5 in HT-29 and 
PANC-1 cell lines. Cell surface expression was evaluated by flow cytometry (A). The relative 
signal is calculated with respect to the control cells stained only with the secondary antibody 
(A). Total protein expression of DR4 and DR5 receptor in HT-29 and PANC-1 cells was 
revealed by Western blotting (B). Data in A were analysed by ANOVA using GraphPad Prism 
6 software and are presented as mean values ± SEM with differences at p ≤ 0.05 considered as 
significant. Presented data A-B are representative of at least three biological replicates.   
 
     For the effective induction of TRAIL-triggered apoptosis were cells HT-29 (Fig. 4.5 A-B) 
or PANC-1 (Fig. 4.6 A-B) pre-incubated with 100 nM HHT for 1 h and then incubated with 
100 ng/ml TST-TRAIL variants for 30 min to 3 hrs (HT-29 cells) or 30 min to 5 hrs (PANC-
A 
B 
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1). As TRAIL-induced apoptosis depends on an efficient attraction and especially processing 
of pro-caspase-8, we initially examined kinetics and efficacy of caspase-8 self-processing and 
cleavage of its downstream target effector caspase-3. In both cell lines was reproducibly 
observed not only more efficient, but also faster activation of both caspases in DR5-specific 
ligands-treated cells comparing  to DR4-specific and WT ligands. Even more, DR5.2 ligand 
excelled in the activation of apoptotic signalling in HT-29 as well as in PANC-1 cells as 
documented by the fastest and efficient self-processing of caspase-8, strongest accumulation of 
processed caspase-3 and additionally also by cleavage of caspase-3 target, PARP protein (Fig. 
4.5 A-B, 4.6 A-B).  
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Figure 4.5: TRAIL-induced processing of caspases-8, caspase-3 and caspase-3 target 
protein PARP in colorectal HT-29 cell line. 
Colorectal HT-29 (A-B) were treated with TST-TRAIL variants. Cells were pre-treated with 
100 nM HHT for 1 h and then treated with 100 ng/ml of TST-TRAIL WT or 4.2, 5.1 and 5.2 
ligands for indicated time periods. The samples were analysed by Western blotting. SE stands 
for the stronger exposition. The Western blots are representative of at least three biological 
replicates.  
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Figure 4.6: TRAIL-induced processing of caspases-8, caspase-3 and caspase-3 target 
protein PARP in pancreatic PANC-1 cell line. 
Pancreatic PANC-1 cells (A-B) were treated with TST-TRAIL variants. Cells were either 
mock-treated (A) or pre-treated with 100 nM HHT for 1 h (B) and then treated with 100 ng/ml 
of TST-TRAIL WT or 4.2, 5.1 and 5.2 ligands for indicated time periods. The samples were 
then analysed by Western blotting. SE stands for stronger exposition. The Western blots are 
representative of at least three biological replicates.   
 
    The data from Western blots pointing to faster and more efficient activation of apoptotic 
signalling by DR5-specific ligands prompted us to compare these apoptotic signalling triggered 
by receptor-specific ligands using more quantitative flow cytometry analyses. Titration of 
TRAIL variants revealed that low, limited TRAIL concentration of 10 ng/ml in HT-29 cells 
pre-treated with 100 nM HHT induced in case of DR5-specific ligands very effective apoptosis 
(40-60% compare to 15-20% induced by DR4-specific ligand or TST-TRAIL WT). However, 
at saturating TRAIL ligands concentration of 100 ng/ml both WT and DR5-selective ligands 
induce in contrast to ligand DR4.2 apoptosis of 70-85% cells (DR4-specific ligands just about 
40%) (Fig. 4.7 A-B). When PANC-1 cells were pre-treated with sensitizers HHT (100 nM) or 
ABT-737 (20 uM), TRAIL-induced apoptotic response was similarly as in HT-29 cells greatly 
enhanced and also DR5-specific ligands showed a better effectivity than WT or DR4-specific 
variant (Fig. 4.7 D). Interestingly, while not pre-sensitized, HT-29 as well as PANC-1 were 
more or less resistant to TRAIL WT-induced apoptosis, but they were both responsive to DR5.2 
ligand (Fig. 4.7 B-C). 
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Figure 4.7: DR5 receptor-specific ligands effectively induce apoptosis in colorectal and 
pancreatic cancer cells. 
HT-29 cells were either mock-treated (B) or pre-treated with 100 nM HHT for 1 h (A) or with 
20 µM ABT-737 for 4 hrs (B), and then treated with increasing concentration (A) or with 100 
ng/ml (B) of TST-TRAIL WT, 4.2, 5.1 and 5.2 for 5 hrs. PANC-1 cells (C-D) were pre-treated 
with 100 nM HHT for 1h or with 20 µM ABT-737 for 4 hrs and then treated with TRAIL 
variants at a concentration of 100 ng/ml for 5 hrs. Cells were assessed for apoptosis using 
annexin V-FITC staining and analysed by flow cytometry (A-D). Data in A-D were analysed 
by ANOVA using GraphPad Prism 6 software and are presented as mean values ± SEM with 
differences at p ≤ 0.05 considered as significant. The presented data are representative of at 
least three biological replicates.  
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4.1.3 Downregulation of anti-apoptotic protein Mcl-1 sensitizes HT-29 cells for DR5 
induced apoptosis 
     One of the main regulators of apoptosis are members of Bcl-2 protein family, from them 
Mcl-1 was shown to be highly expressed pro-survival protein in human malignancies (Tong et 
al., 2017). We previously showed that Mcl-1 is one of the main regulators of TRAIL-induced 
apoptosis of colorectal cancer cells (Beranova et al., 2013). We examined whether and how 
could Mcl-1 also affect TRAIL-induced apoptosis in a receptor-specific manner. We prepared 
several constructs with downregulated Mcl-1 using lentiviral shRNA system (shMcl-1#1-6) and 
non-targeting shRNA control (NT), which were cloned into pLKO1 plasmid (Fig. 4.8 A). For 
further experiments were used HT-29 cells transduced with shMcl-1#6 and non-targeting 
control. Strangely, the lentiviral control transduction using non-targeting shRNA enhanced 
TRAIL-induced apoptosis of HT-29 cells by about 20-30%, with DR5.2 ligand being the most 
effective one (Fig. 4.8 B). However, Mcl-1 downregulation even more enhanced TRAIL-
induced apoptosis of shMcl-1 HT-29 cells. Interestingly, downregulation of Mcl-1 sensitized 
HT-29 cells preferentially to WT- and DR5-specific ligands induced apoptosis, while DR4.2 
ligand did not trigger enhanced apoptotic signalling at all (Fig. 4.8 B).  The flow cytometry data 
were in a good agreement with the Western blotting analysis of caspase-3 processing and the 
cleavage of one of its main targets, PARP protein. Both DR5-specific ligands and to a lesser 
extent also WT-TRAIL induced in time-dependent manner efficient caspase-3 processing (by 
activated caspase-8) and cleavage of PARP and Bid (Fig. 4.8 C). In contrast, DR4-specific 
ligand performed poorly and did not induce any notable caspase-3 processing or PARP and Bid 
cleavage.  
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Figure 4.8: Downregulation of anti-apoptotic protein Mcl-1 sensitizes HT-29 cells to DR5-
induced apoptosis. HT-29 cells were transduced with lentiviruses containing non-targeting 
(NT) shRNA or shMcl-1 shRNA #1-6.  shRNA-mediated suppression of Mcl-1 protein was 
evaluated by Western blotting (A). HT-29 cells expressing non-targeting or shMcl-1#6 were 
treated with 100 ng/ml of TST-TRAIL WT, 4.2, 5.1, 5.2 for 3 hrs (B) or for increasing time 
periods (C). Cells were analysed either by flow cytometry (B) or by Western blotting (C) Data 
in Fig. 4.8 B were statistically evaluated by ANOVA using GraphPad Prism 6 software and are 
presented as mean values ± SEM with differences at p ≤ 0.05 considered as significant. The 
presented data are representative of at least three biological replicates. 
 
4.1.4 TRAIL receptor-specific variants do not differ in the formation of death-inducing 
signalling complex in HT-29 and PANC-1 cells 
     Observed differences in signalling efficacy among the analysed TRAIL receptor specific 
ligand (caspase processing and induction of apoptosis) prompted us to turn our attention to the 
formation and composition of the death-inducing signalling complex (DISC). The apoptotic 
signalling induced by ligand TRAIL could be regulated at many steps and DISC formation is 
the first and most important one. The dynamics of DISC formation or ratio of individual 
components could reveal an underlying mechanism behind the more effective induction of 
C 
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apoptotic signalling by DR5 specific ligands. For DISC analyses we took advantage of the 
Twin-strep tag that was also used for the purification of recombinant ligands from the E.coli 
clarified lysates. The Twin-strep tag (TST) very strongly and with high affinity binds to 
Streptactin-Sepharose and thus TST-tagged TRAIL ligands are superior for the efficient pull-
down of the TRAIL DISC complexes. HT-29 (Fig. 4.9 A-B) and PANC-1 cells (Fig. 4.9 C-D) 
were treated with 1 µg/ml of WT, 4.2, 5.1 and 5.2 TST-TRAIL variants and the relevant DISC 
complexes were isolated using Streptactin Sepharose. Affinity purification of DISC 
components in HT-29 cells first of all revealed specific interaction of the receptor-specific 
ligands (in contrast to WT ligand, which precipitated both DR4 and DR5 receptors) with their 
cognate receptors again confirming their selectivity (Fig. 4.9 A-D, DISC parts).  DISC analyses 
pointed to some noticeable differences in either DISC composition or in the kinetics of their 
formation (Fig. 4.9 A-D). We noticed that TRAIL WT as well as DR4-specific ligand attracted 
in contrast to DR5-selective ligands (especially to DR5.1 ligand) in both HT-29 and PANC-1 
cells fairly more FADD adapter protein (both during pre-incubation on ice and in the course of 
DISC formation/processing) (Fig. 4.9 A-D). Interestingly, though both DR5-selective ligands 
attracted significantly less FADD, their caspase-8 processing in DISC complexes was quite 
efficient and in case of DR5.2-treated PANC-1 cells even superior to all other ligands (Fig. 4.9 
D). More efficient caspase-8 activation by DR5-selective ligands was also reflected in 
significantly more effective caspase-8 processing in cell lysates of both model cell lines (Figs. 
4.9  A-D).  
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Figure 4.9: TRAIL receptor-specific variants efficiently and selectively induced DISC 
formation in HT-29 cells. 
HT-29 (A-B) cells were pre-incubated with 1 mg/ml of TST-TRAILs: WT, 4.2, 5.1 and 5.2 for 
15 min on ice. The cells were then either harvested (time point 0 min) or transferred to 37°C, 
harvested at specified time periods (10, 20 and 40 min) and lysed. The DISC complexes from 
 
 
 
                        
 
 
                      0´  10´   20´  40´  0´   10´   20´  40  ´0´  10´  20´  40´
WT 4.2 5.2
 Mw/kDa
HT-29
   0´  10´   20´  40´   0´  10´  20´  40´  0´   10´    20´   40´
WT 4.2 5.2
 Mw/kDa
β-actin
DR-4
DR-5
FADD
Caspase-8
Caspase-8 cl.
FLIP-L cl.
FLIP-S
48
48/40
55/53
43/41
55
28
25
42
43
                                
                       
           
DR-4
DR-5
FADD
Caspase-8
Caspase-8 cl.
FLIP-L cl.
FLIP-S
48
48/40
55/53
43/41
28
25
43
DISC
C
el
l l
ys
at
es
                       
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                        
FLIP-L
B 
75 
 
the cleared lysates were isolated on Streptactine agarose and analysed by Western blotting. 
Presented data are representative of two biological replicates. 
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Figure 4.9: TRAIL receptor-specific variants efficiently and selectively induced DISC 
formation in PANC-1 cells. 
PANC-1 (C-D) cells were pre-incubated with 1 mg/ml of TST-TRAILs: WT, 4.2, 5.1 and 5.2 
for 15 min on ice. The cells were then either harvested (time point 0 min) or transferred to 37°C, 
harvested at specified time periods (10, 20 and 40 min) and lysed. The DISC complexes from 
the cleared lysates were isolated on Streptactine agarose and analysed by Western blotting. 
Presented data are representative of two biological replicates. 
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4.1.5 DR5 but not DR4 downregulation results in lower susceptibility of colorectal 
cancer cells to TRAIL 
     In order to further decipher and confirm the major role of the DR5 receptor in TRAIL-
triggered apoptotic signalling, we employed DR4- or DR5-specific lentiviral shRNA constructs 
to downregulate their expression in HT-29 cells. We prepared several shRNA constructs sub-
cloned into pLKO vector, two different DR4 specific shRNA namely shDR4#01 and shDR4#02 
and three different DR5-directed lentiviral shRNAs: shDR5#01, shDR5#04 and shDR5#05. We 
also included the non-targeting shRNA (NT) and empty pLKO1 (EV) controls and prepared the 
recombinant lentiviruses for all above-mentioned plasmids. HT-29 cells were then transduced 
using these lentiviral particles and transduced cells were selected by puromycin. Analysis of 
the total level of receptors (Fig. 4.10 A) and their cell surface externalisation (Fig. 4.10 B) 
confirmed that both DR4-targeting shRNAs efficiently suppressed its expression in HT-29 
cells. shRNA against DR5 receptor decreased expression of DR5 receptor in all three cases, but 
mostly in shDR5#05 (Fig. 4.10 B). For further functional analyses were used shDR5#04 and 
shDR5#05. Interestingly, we also observed that the cell surface expression of DR4 was in DR5-
downregulated cell lines slightly elevated and vice versa in DR4-downregulated cell lines DR5 
expression was also increased (Fig. 4.10 A-B).   
     Apoptotic test using DR4- or DR5-selective ligands indeed confirmed that the 
downregulation of a respective cognate receptor to various degree attenuated apoptotic 
signalling induced by respective receptor-specific ligands. (Fig. 4.11 B-D). In case of DR4.2 
ligand apoptosis of HT-29 transduced with shDR4#01 or shDR4#02 was greatly reduced in 
both cell lines (Fig. 4.11 B). DR5 receptor selective ligands 5.1 and 5.2 induced apoptosis of 
HT-29 cells with downregulated expression of DR5 was also attenuated with shDR5#05 being 
more effective (Fig. 4.11 C-D). Notably, while apoptosis triggered by TST-TRAIL WT (Fig. 
4.11 A) was almost unaffected in HT-29 cells with suppressed expression of DR4, 
downregulation of DR5 by shRNA#04 and #05 significantly attenuated TST-TRAIL WT-
induced apoptosis in these cells, thus supporting the major role of DR5 receptor in apoptotic 
signalling in HT-29 cells. 
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Figure 4.10: shRNA mediated downregulation of DR4 and DR5 receptor. Total cellular (A,  
Western blotting) and the cell surface (B, flow cytometry) protein expression. Relative 
fluorescence signal B was normalised to the level of the signal after staining with secondary 
antibody only and then against the receptor expression in cells expressing non-targeting (NT) 
control shRNA. Data from three biological replicates were analysed by ANOVA using 
GraphPad Prism 6 software and are presented as mean values ± SEM with differences at p ≤ 
0.05 considered as significant.  
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Figure 4.11: DR5 but not DR4 downregulation attenuates TST-TRAIL WT induced 
apoptosis of HT-29 cells. For the enhanced induction of apoptosis (A-D), HT-29 were pre-
treated with 100 nM HHT for 1 h and then treated with 100 ng/ml TRAIL WT (A) or TRAIL 
receptor specific variants (B-D) for 3 h. TRAIL-induced apoptosis was quantified using annexin 
V-FITC staining and flow cytometry. Data in Fig. 4.11 A-D (three biological replicates) were 
analysed by ANOVA using GraphPad Prism 6 software and are presented as mean values ± 
SEM with differences at p ≤ 0.05 considered as significant.  
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4.1.6 Both DR4 and DR5 receptor-specific ligands efficiently induce necroptosis in HT-
29 cells 
     Besides inducing apoptosis, activated death receptors can, upon inhibition of apoptosis, 
trigger a regulated necrotic cell death - necroptosis. We examined the efficacy of TRAIL 
receptor-specific ligands in the induction of necroptotic signalling. Efficient induction of death 
receptors (including TRAIL receptors) triggered necroptosis requires blocking caspase activity 
e.g. with pan-caspase inhibitor z-VAD, and in addition cytosolic availability of RIPK1, an 
essential component of the necrosome - necroptosis-activating intracellular complex. RIPK1 is 
in cells often ubiquitinated by cIAP1/2 (especially in activated death receptors DISCs) and thus 
unavailable for the necrosome formation. Therefore, using IAP inhibitor/SMAC mimetic such 
as birinapant, which suppresses cIAP1/2 expression and thus increases the cytosolic pools of 
RIPK1, is recommended for efficient induction of DR-mediated necroptosis. Necroptotic 
character of the cell death was confirmed using known inhibitors of necroptosis - RIPK1 
inhibitor necrostatin-1 and MLKL assembly inhibitor necrosulfonamide. Initially we titrated 
TST-TRAIL WT and assessed an effective concentration of the ligand to induce necroptosis of 
HT-29 cells (pre-treated with zVAD and birinapant). The titration uncovered that TST-TRAIL 
WT efficiently induced necroptosis of about 60% of HT-29 cells even at the low concentration 
of 10 ng/ml, which just slightly increased at saturating TST-TRAIL WT concentration 100 
ng/ml to about  65-67% of dead, PI-positive cells. Necroptotic mode of this cell death was 
confirmed by its efficient suppression with either RIPK1 inhibitor necrostatin-1 (Fig. 4.11 A-
B) or the MLKL inhibitor necrosulfonamide  (Fig. 4.11 B). Necroptotic character of HT-29 cell 
death was also supported by confirming RIP3 kinase-mediated phosphorylation of the 
necroptosis effector MLKL protein and by the absence of caspase-3-processed PARP (Fig. 4.11 
D). Interestingly and in a contrast to apoptotic signalling, we did not notice any significant 
differences between DR4- and DR5-specific ligands in inducing necroptotic cell death at high, 
saturating concentrations of the ligands (100 ng/ml) (Fig. 4.11 B). However, at low 
concentration (10 ng/ml and less) of the TST-TRAIL ligands, DR5-selective ones (notably 
DR5.2) were significantly more effective than TST-TRAIL WT of the TST-TRAIL DR4.2 
ligand (Fig. 4.11 C).  
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Figure 4.12: Both DR4 and DR5 receptor-specific TRAIL ligands efficiently induce 
necroptosis in HT-29 cells. HT-29 cells were pre-treated with combinations of 10 nM 
birinapant plus 50 µM z-VAD +/- 50 µM necrostatin-1 for 1 h and then treated with increasing 
concentration of TST-TRAIL WT for 8 hrs (A). HT-29 were pre-treated with the combinations 
of 10 nM birinapant, 50 µM z-VAD +/- 50 µM necrostatin-1 or 20 µM necrosulfonamide for 1 
h, and then treated with 100 ng/ml of TST-TRAIL WT, 4.2, 5.1 and 5.2 for 8 hrs (B). HT-29 
cells were pre-incubated with 10 nM birinapant and 50 µM z-VAD for 1 h and then treated with 
increasing concentrations of TST-TRAIL ligands for 6 hrs (C). Cell death was in all cases 
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quantified by propidium iodide staining and flow cytometry. HT-29 cells were pre-treated with 
the combination of 10 nM birinapant, 50 µM z-VAD and 50 µM necrostatin-1 for 1 h, and then 
TRAIL ligands were added at the concentration of 100 ng/ml for 3hrs (D). Samples were 
analysed by Western blotting. Data in Fig. 4.11 A-C were analysed by ANOVA using GraphPad 
Prism 6 software and are presented as mean values ± SEM with differences at p ≤ 0.05 
considered as significant. The presented data are representative of at least three biological 
replicates. 
 
4.1.7 DR5 receptor-specific TRAIL ligands efficiently induce NF-κB, p38 and JNK 
signalling under both apoptotic and necroptotic conditions 
     Along the induction of cell death, ligands from the TNF family can upon binding to their 
cognate receptors activate a number of non-apoptotic signalling pathways such as the NF-κB, 
MAP and stress kinases that might drive cell proliferation, migration and even grant cell 
survival.  Similarly, as for the apoptotic and necroptotic signalling, we were interested whether 
and how TRAIL receptor-specific ligands might also affect these auxilliary signallings  in HT-
29 or PANC-1 cells under either pro-apoptotic or pro-necroptotic conditions. We examined an 
effect of receptor-specific TRAIL variants on the activation of NF-κB, MAP kinase p38 and 
stress kinase JNK in these cells. In general, under pro-apoptotic conditions, DR4-specific 
TRAIL variant was less effective in the efficacy of activation of these signalling pathways both 
in HT-29 and PANC-1 cells (Fig. 4.13 A-B). Notably, activation/phosphorylation of JNK 
kinases and IκB phosphorylation was very inefficient in TST-TRAIL DR4.2-treated HT-29 
cells and apparently less efficient also in PANC-1 cells. Under necroptotic conditions, these 
differences among receptor-specific TRAIL variants were blunted in TST-TRAIL-treated HT-
29 cells (Fig. 4.13 C), possibly reflecting similar efficacy of wild-type and receptor-specific 
variants in triggering necroptosis of HT-29 cells. 
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Figure 4.13: DR5 receptor-specific TRAIL ligands effectively induce NFκB, p38 and JNK 
signalling under apoptotic and necroptotic conditions. 
HT-29 cells (A) and PANC-1 (B) were treated with 100 ng/ml of TST-TRAIL WT, 4.2, 5.1 and 
5.2 for 60-180 min (A, B) or were pre-treated with both 10 nM birinapant and 50 µM z-VAD 
for 1 h and then treated with 100 ng/ml of TST-TRAIL ligand variants for 60-180 min (C). Cell 
lysates were analysed by Western blotting. SE stands for the stronger exposition. The presented 
data are representative of at least three biological replicates. 
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4.1.8 TRAIL ligands upregulate mRNA expression of several cell death-related genes 
including DR4 and DR5 receptors 
     To further explore the TRAIL signalling induced by different receptor specific TRAIL 
ligands and being puzzled by our finding that shRNA-mediated downregulation of DR4 
receptor slightly enhanced cell surface expression of DR5 receptor and vice versa (see Fig. 
4.10) we examined an effect of TRAIL ligand variants on the mRNA expression of receptors 
DR4 and DR5 and some other cell death-related genes (cIAP1/2). Interestingly, we found that 
treatment of HT-29 cells with TST-TRAIL WT and DR5 specific TRAIL ligands in HT-29 
cells for different time periods led to increased mRNA expression of DR4 receptor (Fig. 4.14 
A). Similarly, TST-TRAIL WT and DR5 selective ligands also enhanced mRNA expression of 
DR5 (Fig. 4.14 B). The increase of DR4 and DR5 mRNA expression was traceable after 2 and 
4 hours and declined after 8 hours of incubation of HT-29 with TRAIL ligands. Likely we 
observed increased levels of both cIAPs mRNA using all TRAIL ligands but mostly in case of 
TST-TRAIL DR5.01 and DR5.02. 
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Figure 4.14: TRAIL ligands induce up-regulation of DR4, DR5 and cIAP1/2 mRNAs 
expression in HT-29 cells. HT-29 cells were treated with 100ng/ml TST-TRAIL ligands WT, 
4.2, 5.1, 5.2 for 2, 4 and 8 hrs and mRNA for DR4 (A), DR5 (B), cIAP1 (C), cIAP2 (D) were 
quantified by RT-qPCR. Samples were normalized to 4 house-keeping genes GAPDH, β-actin, 
RPL37A and SDH. Ctrl.1 and ctrl.2 are non-treated cells. Data were analysed by GraphPad 
Prism 6 software and the presented data are representative of at least two biological replicates. 
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4.2 Human embryonic and induced pluripotent stem cells express TRAIL 
receptors and can be sensitized to TRAIL-induced apoptosis 
 
Summary 
     Inducing of apoptotic signalling in somatic cells is broadly characterised but not much is 
known about regulated cell death occuring in human stem cells. In colaboration with prof. Ales 
Hampl laboratory we tried to describe several main inducers of apoptosis from TNFR receptor 
family, which are well known triggers of cell death in somatic cells. We were interested whether 
essential components of these pathways are expressed and able to activate cell death in human 
embryonic stem cells (hESC) and human-induced pluripotent stem cells (hiPSC). Even though 
both cell types expressed TNFR1, DR4/5 receptors and proteins inevitable for efficient 
induction and progression of extrinsic apoptotic signalling , they were not responsive to TRAIL 
induced apoptosis. Using inhibitor of translation homoharringtonine (HHT) resulted in 
sensitizig of hESC and hiPSC cell lines to TRAIL induced apoptosis. Further experiments 
revealed that HHT treatment caused decrease of anti-apoptotic proteins cFLIP and Mcl-1, 
which in combination with TRAIL ligand enhanced processing of initiator caspase-8 and 
downstream effector caspase-3. Downregulation of cFLIP protein by shRNA proved the 
important regulatory function of this protein in TRAIL-induced apoptosis in hESC and hiESc. 
We provided the first evidence that, irrespective of their origin, human pluripotent stem cells 
express canonical components of the extrinsic apoptotic system and on stress can activate death 
receptor-mediated apoptosis. 
 
Declaration of honour 
     Author contributed to this project by preparing cell line with downregulated cFLIP. Initially 
were prepared lentiviral particles containing either non-targeting (in this work shown as non-
silencing NS) control shRNA and two shRNA against cFLIP subcloned into pLKO plasmid 
containing puromycine resistance. These lentiviral particles were purified as described in 
Materials and Methods and subsequently used for transduction of hESC cell line. Transduced, 
puromycin-resistant cells were selected and used in further experiments as showed in Fig. 4.15-
4.16. Experiments in Fig. 4.15-4.16 were done in prof. Ales Hampl laboratory, Department of 
Histology and Embryology, Faculty of Medicine, Masaryk University, Brno, Czech Republic 
by Vladimir Vinarsky and his colleagues.  
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4.2.1 cFLIP represents a safeguard protecting human pluripotent stem cells against 
TRAIL-induced apoptosis 
     In our previous work from Beranova et al., we showed that homoharringtonine (HHT) is a 
potent sensitizer for TRAIL induced apoptosis in several colorectal cancer cell lines. Sensitizing 
effect of homoharringtonine is mainly mediated through downregulation of cFLIP and Mcl-1 
anti-apoptotic proteins. In this work Vinarsky et al. showed that human hESC and hiPSC were 
resistant to TRAIL-induced apoptosis and could be sensitized by using HHT. To address a role 
of cFLIP and Mcl-1 in resistance of hESC to TRAIL-induced apoptosis were prepared 
recombinant lentiviruses expressing shRNA specific to each of these proteins, one non-
targeting control (non-silencing NS), two different shRNA against cFLIP (shFLIP1/2) and three 
shRNA for Mcl-1. Selected cells were tested for downregulation of either of the protein as 
showed for cFLIP in Fig. 4.15 A (only shFLIP1 is shown), downregulation of Mcl-1 was not 
successful (data not shown). Photo in Fig. 4.15 B displays the light microscopy of non-treated 
and TRAIL-treated NS and shFLIP1 transduced cell lines. While non-treated or NS transduced 
TRAIL treated cells had no morphological features of apoptosis, cells with downregulated 
cFLIP and treated with 200 ng/ml of TRAIL WT ligand showed rounded and detached 
morphology after 6 hours of treatment. This observation was also confirmed by flow cytometry 
with antibody specific for PARP cleavage where was revealed significant increase in apoptotic 
cell death in shFLIP1 cell line (Fig. 4.15 C). Consistently with previous results apical caspases-
8 and -10 and effector caspase-3 manifested pronounced cleavage in case of shFLIP1 (Fig. 4.15 
D). It was published that cFLIP could contribute to not only apoptosis but also could prevent 
cells from necroptotic cell death (He et al., 2013). The exclude the possibility of contribution 
of necroptosis to the pool of observed dead cells, were cells exposed to pan-caspase inhibitor 
Z-VAD-FMK and caspase-8 inhibitor Z-IETD-FMK, respectively, cells were also treated with 
inhibitor of RIPK1 necrostatin-1, which is supposed to inhibit necroptotic signalling pathway. 
In these conditions, no changes in proceeding cell death were determined either by specific 
antibody against cleaved PARP1 (Fig. 4.16 A) or by DNA content release by subG1 method 
(Fig. 4.16 B) in cell lines with NS shRNA or shRNA against cFLIP when using necrostatin-1. 
On the contrary both caspase inhibitors were able to inhibit either cell death measured by flow 
cytometry or detected by cleavage of caspase-8 and -3 on Western blot (Fig. 4.16 A-C). 
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Figure 4.15: Knock-down of cFLIP sensitizes hESC to TRAIL-induced apoptosis. hESC 
line CCTL14 was transduced using lentiviruses expressing non-silencing shRNA (NS) or 
shRNA targeting cFLIP mRNA (shFLIP1). Western blot showing a decrease in cFLIP levels in 
shFLIP1-transduced cells comparing to NS cells (A). Nontransduced (WT), NS shRNA-
transduced and shFLIP1-transduced cells were left untreated (control) or treated with 
200 ng/mL TRAIL for 6 h. Induction of apoptosis was determined by light microscopy showing 
morphology of colonies and cell detachment (B) or by staining with antibody specific to PARP 
cleavage and analysed by flow cytometry (C). Western blot analysis of the activation of the 
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extrinsic apoptotic pathway in NS shRNA and shFLIP1-transduced cells after 30 min and 1, 2, 
3, and 6 h of treatment with 200 ng/mL TRAIL (D) . Data in C were analysed by ANOVA using 
GraphPad Prism 6 software and are presented as mean values ± SEM with differences at p ≤ 
0.05 considered as significant. The presented data are representative of three biological 
replicates. 
 
 
 
 
 
Figure 4.16 Caspase inhibitors suppressed TRAIL-induced apoptosis of hESCa with 
downregulated expression of cFLIP. Non-silencing (NS) shRNA and shFLIP1 cells were 
untreated (control), treated with 200 ng/mL TRAIL, or co-treated with 200 ng/mL TRAIL and 
20 mM Z-VAD-FMK, Z-IETD-FMK or necrostatin-1. Induction of apoptosis was determined 
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by staining with an antibody specific to cleaved PARP (A) or determined by DNA content 
realease (B) and analysed by flow cytometry. Western blot analysis of activation of the extrinsic 
apoptotic pathway in cells with down-regulated expression of cFLIP after 3 h of treatment (C). 
Data in A-B were analysed by ANOVA using GraphPad Prism 6 software and are presented as 
mean values ± SEM with differences at p ≤ 0.05 considered as significant. The presented data 
are representative of three biological replicates. 
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4.3 Streptomycetes metabolites of the Manumycin family can via enhanced 
production of reactive oxygen species sensitize colon cancer cells to 
TRAIL-induced apoptosis (not published) 
 
Summary 
     One of the main limitation of a use of TRAIL-induced apoptosis in cancer therapy is an 
acquired resistance of tumour tissue to its induction.  Currently a number of chemical enhancers 
or sensitizers of TRAIL-induced apoptosis is being proposed including those targeting known 
anti-apoptotic proteins such as cFLIP and Mcl-1 targeting HHT or Bcl-2 proteins antagonists 
ABT-199 and ABT737 (Beranova et al. 2013, Konopleva et al., 2006). In colaboration with Dr. 
Petr Bartunek´s Laboratory of  cell differentiation (Institute of Molecular Genetics, AV CR) 
we, in high throughput screenings  for senziters of TRAIL induced apoptosis, identified 
Manumycin A as a compound strongly enhancing TRAIL-induced apoptosis of human 
colorectal carcinoma cell lines. In follow-up experiments we in addition to Manumycin A 
analysed effect of its relatives Manumycin B and Asukamycin, all of them known as inhibitors 
of farnesyltransferases (proteins responsible for post-translational modulation and maturation 
of Ras proto-oncogene). In our work we aimed to explore a mechanism of Manumycin A-
mediated senzitization of colorectal carcinoma cell lines to TRAIL induced apoptosis.  
Declaration of honour 
     Author participated in this project by measuring apoptosis in RKO and SW-620 cell lines 
and by measuring production of mitochondrial ROS after cell treatment with Manumycin A, 
Manumycin B and Asukamycin in Fig. 4.17 B and 4.19 respectively. Western blots and 
detection of caspase activation in Fig. 4.18 was performed by Martin Klíma. 
 
4.3.1 Manumycin A but not related Manumycin B or Asukamycin strongly enhances 
TRAIL- and BH3 analogs-induced apoptosis of resistant human colorectal cancer 
cells. 
     High throughput screening analysis of Manumycins-mediated enhancement of TRAIL-
induced apoptosis of colorectal carcinoma cells lines showed that Manumycin A was superior 
to to its analogs Manumycin B and Asukamycin (Fig. 4.17 A) in their sensitizing to TRAIL-
induced apoptosis (Fig.4.17 B). Both colorectal carcinoma cell lines SW-620 and RKO are 
resistant to TRAIL- and BH3 analogues-induced apoptosis however upon their pre-incubation 
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with Manumycin A (and to some extent also with Manumycin B) became largely sensitized to 
apoptosis induced by either of these agents. Interestingly another analogue Asukamycin was 
largely ineffective in enhancing apoptotic signalling (Fig. 4.17 B).  
      Enhancing effect of Manumycin A on TRAIL-induced apoptosis of RKO and SW-620 cells 
was also confirmed by Western blotting of cell lysates from treated colorectal cancer cells.  As 
one can see on Fig. 4.18 pre-treatment with Manumycin A strongly enhanced self-processing 
and cleavage of caspases - 3 and -9 as well as some of their targets (caspase-8-cleaved Bid and 
caspase-3-cleaved XIAP) and thus further confirmed sensitizing effect of Manumycin A on 
TRAIL-induced apoptosis.    
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Figure 4.17: Manumycin A to lesser extent Manumycin B but not Asukamycin enhance 
TRAIL- or BH3 analogues-induced apoptosis of resistant human colorectal cancer cells. 
The structure of Manumycin A, Manumycin B and Asukamycin (A). For the quantification of 
apoptosis SW-620 and RKO colorectal cancer cells were treated with inhibitors 20 µM ABT-
199/737, 50 ng/ml His-TRAIL ligand WT or combination with 10 µM of Manumycin A, 
Manumycin B and Asukamycin for 3 hrs. Cells were evaluated for apoptosis using annexin V-
FITC and analysed by flow cytometry (B). Data in B were analysed by ANOVA using 
GraphPad Prism 6 software and are presented as mean values ± SEM with differences at p ≤ 
0.05 considered as significant. The presented data are representative of two biological replicates 
for RKO cell line and three biological replicates for SW-620.  
 
 
B 
99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18: Manumycin A enhances TRAIL-triggered activation and activity of caspases. 
RKO or SW-620 cells were incubated with Manumycin A, TRAIL and their combination for 3 
and 6 hrs and their lysates were analysed by Western blotting using antibodies given on the 
right. The Western blot is a representative of at least three biological replicates. 
 
4.3.2 Manumycin A triggers mitochondrial ROS production 
      From previous results we observed the strong cleavage of apical caspase-9 in Manumycin 
A-pre-treated cells, which might indicate involvement of mitochondria induced apoptotic 
signalling such as increased ROS production. In order to test this hypothesis, three colorectal 
carcinoma cell lines HT-29, RKO and SW-620 were analysed for production of mitochondria 
induced ROS by using MitoSOX™ Red Mitochondrial Superoxide Indicator. Importantly, all 
three cell lines showed significantly increased production of ROS after Manumycin A 
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treatment, to notably lesser extent after Manumycin B treatment  but no enhanced ROS 
production  in Asukamycin-treated cells (Fig. 4.19). 
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Figure 4.19: Manumycin A triggers significant elevation of mitochondria produced ROS 
in human colorectal cancer cells. HT-29, SW-620 and RKO colorectal cancer cells were 
treated with 10 µM of Manumycin A, Manumycin B and Asukamycin for 3 hrs and then ROS 
production was measured using MitoSOX™ Red Mitochondrial Superoxide Indicator and 
fluorescence signal in PE channel was detected by flow cytometry. Relative fluorescence signal 
was determined as mean fluorescence signal relative to control (media). Data were analysed by 
ANOVA using GraphPad Prism 6 software and are presented as mean values ± SEM with 
differences at p ≤ 0.05 considered as significant. The presented data are representative of two 
biological replicates. 
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5 DISCUSSION 
5.1 TRAIL induces apoptosis but not necroptosis in colorectal and 
pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor 
     Dysregulation of apoptosis belongs among fundamental features of cancer progression 
(Hanahan and Weinberg, 2011). Therefore discovery and clinical use of cancer cell death 
promoting or enhancing drugs is one of the essential goals of cell death-related research. 
Identification of TRAIL ligand as a selective inducer of apoptosis in cancer cells led to the 
development of TRAIL receptor agonists (Yuan et al., 2018). In addition to its selectivity 
towards cancer cells, the use of TRAIL agonists in tumour therapy might take an advantage 
from being supported by other drugs with apoptosis-sensitizing effect. Importantly, apoptosis 
induced by these agonists is triggered even in human tumours with mutated p53 tumour 
suppressor. Two kinds of TRAIL agonists have been developed and tested in clinical studies: 
recombinant proteins and agonistic antibodies. Dulanermin, a zinc-coordinated, homotrimeric 
recombinant protein consisting of 114-281 amino acids of the endogenous polypeptide and 
recently other recombinant IgG fusion ligand ABBV-621 entered clinical trials. Apart from 
recombinant TRAIL ligands a number of agonistic antibodies targeting DR4 or DR5 
(conatumumab, lexatumumab, mapatumumab etc.) were or are being either alone or in 
combination with other anti-cancer drugs evaluated in phase I-II clinical trials. Albeit all TRAIL 
agonists used in clinical trials were well tolerated, no statistically significant anticancer activity 
was achieved. Moreover many cancer cell lines were found to be resistant to TRAIL-induced 
apoptosis. Though unsuccessful, the outcome from the trials might lead to the formulation of 
better and possibly patient-tailored therapeutic protocols, which include the use of novel 
sensitizers of TRAIL-induced apoptosis in resistant cancer cells and the discovery and 
preparation of modified TRAIL-based agents (e.g. HERA-TRAIL/ABBV-621). 
 
     In the fundamental part of this study we focused on the receptor-selective analysis of 
TRAIL-induced signalling in human cells. The promiscuity of TRAIL ligand for binding of 
five different receptors, three of them non-apoptotic, and formation of hetero-trimeric non-
apoptotic complexes of DR4/DR5 with decoy receptors Dcr1/DcR2 encouraged the concept 
that death receptor specific selectivity could be the possible way to find more potent inducers 
of TRAIL triggered apoptosis. Differential contribution of either of the TRAIL receptor was 
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already proposed in several reports in cancer cells of various origin  but no detail study dealing 
with all TRAIL receptors specific signalling outcomes was published so far (Kelley et al., 2005; 
MacFarlane et al., 2005; Lemke et al., 2010; Lemke et al., 2014). Thus our systemic approach 
using modified/enhanced DR4- and DR5-selective ligands might be in addition to enhanced 
systemic knowledge of their signalling of a potential applied outreach in tailoring cancer 
therapy in TRAIL receptor-selective way.  
5.1.1 Preparation of TRAIL receptor-specific ligands 
      Our novel/upgraded soluble recombinant ligands are composed of the extracellular region 
of human TRAIL with amino acids 95-281 containing, in addition to the mutated extracellular 
part of TRAIL, trimerisation/stabilisation (TRI) motif and TwinStrep tag at their N-termini. 
Moreover, trimerisation of DR receptors is required for effective induction of apoptosis and 
thus agonistic antibodies are rather weak inducers of apoptosis due to their bivalent nature 
allowing only dimerization of TRAIL receptors. To enhance purification and stability of the 
recombinant TRAIL a number of approaches introducing different tags (His, Flag,) and 
trimerising domains (leucine zipper (LZ) or isoleucine zipper (iz)) were developed. Though 
some of these tags extended the stability of recombinant proteins, they were also accompanied 
by increased hepatotoxicity in vivo (Yuan et al., 2018). In our modified recombinant TRAIL 
ligands, T4 phage trimerisation/stabilisation (TRI) motif enhances stability and trimeric state 
of the ligands and the Twin Strep tag allowed (in addition to its use for the purification of E.coli-
expressed recombinant ligands) the most effective approach for the purification of TRAIL 
DISC complexes (Papanikolopoulou et al., 2005). A selective and computer design-based point 
mutations of sequence of human TRAIL ligand led to the preparation of novel highly active 
and DR4- or DR5-specific variants of the ligand. These mutations were published to be 
selective for each cognate receptor and efficiently induced apoptosis in cancer cells (Gasparian 
et al., 2009; Reis et al., 2010; van der Sloot et al., 2006).  
5.1.2 TRAIL-induced apoptosis 
      Efficacy and selectivity testing of our modified TRAIL receptor-specific ligands was 
carried out using hematopoietic cell lines Ramos and Jurkat, which were previously shown to 
transduce apoptotic signalling in TRAIL receptor-specific manner (Jang et al., 2003; Sung et 
al., 2009). The modified DR4- and DR5- targeted TRAIL variants were, as expected from 
already published data, highly selective, inducing apoptosis more efficiently than TST-TRAIL 
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WT via DR5-mediated signalling in Jurkat T cells or DR4-mediated signalling in Ramos B 
cells.  
     For detailed analysis of DR4- vs. DR5-specific signalling were chosen as model cell lines, 
colorectal HT-29 and pancreatic PANC-1 cells. We confirmed the published data that these 
cells are resistant to TRAIL WT-induced apoptosis and thus for its enhancement we used two 
types of enhancing agents: a/ inhibitor of translation homoharringtonine (HHT), which 
downregulates expression of short-lived anti-apoptotic protein cFLIP and Mcl-1 or b/ Bcl-
2/Bcl-XL inhibitor ABT-737. The detail analysis of TRAIL receptor specific ligands signalling 
in colorectal HT-29 cells revealed that DR5-specific ligands are more effective than DR4-
targeted ligands or even wt TRAIL in the activation of caspases and following initiation of 
apoptosis in HT-29 cells. Interestingly, early apoptotic process of DISC formation proceeded 
similarly for the TST-TRAIL WT and all TRAIL receptors-specific variants in HT-29 cells, 
suggesting enhanced downstream processing of caspase-8 in cells treated with DR5-selective 
ligand. This phenomenon could for example happen due to different turn-over of DISC proteins. 
In support of this option, two articles published by McDonald and col. and Jin and col. suggest 
that caspase-8 ubiquitination influences the processing of available caspase-8 cellular pool 
(McDonald et al., 2004; Jin et al., 2009).       
     Majority of so-far published data point to DR5 receptor as a dominant receptor signalling in 
TRAIL-induced apoptosis in colorectal cancer cells (Kelley et al., 2005; Mohr et al., 2015). 
However, recently published data by Dufour and col. obtained using DR4 or DR5 gene editing 
in HCT-116 and SW-480 colorectal cancer cells, show a bit contradictory outcome (Dufour et 
al., 2017). Cells with inactivated expression of DR4 become upon induction of ER stress 
resistant to His TRAIL or DR5 receptor specific antibody lexatumumab, pointing to DR4 as a 
main apoptotic receptor in ER induced apoptosis. Similarly Glab and col. published that DR5 
and even caspase-8 are dispensable for ER induced apoptosis (Glab et al., 2017). However, 
their data became later questioned by Lam and his colleagues who used the same cell lines but 
were not able to reproduce the same results and confirmed the dominant role of DR5 in ER-
induced apoptosis (Glab et al., 2017; Lam et al., 2018). Additionally, other recent report 
documents that DR5 receptor is the one, which responds to stress triggered by unfolded protein 
response (Lu et al., 2014).  Our data obtained using modified TRAIL receptor-specific mutants 
support major impact of DR5-triggered apoptotic signalling in colorectal HT-29 cells. In 
addition to apoptosis, DR5-selective ligands are also superior to DR4-selective ligand in the 
activation of auxiliary signalling (stress kinases and NFkB). Especially strong DR5.2-mediated 
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activation of the long isoforms of JNK1 kinase might enhance DR5-triggered apoptotic 
signalling in colorectal cancer cell lines (Mahalingam et al., 2009). Our results are additionally 
supported by shRNA-mediated knockdown of either DR4 or DR5 expression in HT-29 cells, 
which in contrast to gene editing-mediated inactivation of these receptors, do not entirely 
eliminate the expression of either of these receptors, and thus allow for their possible cross-talk. 
In addition, we found that engagement of DR5 receptor led to an increase in the transcription 
of DR5 gene, which could lead to increased level of DR5 receptor and subsequent more efficient 
DR5 triggered apoptosis. Moreover, several reports document that ubiquitin mediated 
degradation preferentially targets DR4 receptor, which also likely contributes to the enhanced 
DR5-mediated apoptotic signalling (Liu et al., 2007; Song et al., 2010; van de Kooij et al., 
2013). However, DR4/DR5 requirement is likely cell/cancer specific and in some cells could 
be DR4 required to support DR5-mediated signalling and thus its deletion could severely 
compromise DR5-triggered apoptosis. From the reasons mentioned above and according to our 
and recently published data we believe that DR5 receptor is a dominant inducer of apoptosis in 
colorectal cancer cells. An interesting work from posttranslational modification of TRAIL 
receptors might be also behind different response of cancer cells to DR5- or DR4-specific 
signalling. Colorectal cancer cells which are not responsive to DR5, but are responsive to DR4 
(DLD-1 and HCT-116) have decreased levels of fucosyltransferase 3 (FUT3) and -6 (FUT6), 
enzymes responsible for the fucosylation of DR5 receptor in colon cancer cells. Ectopic 
expression of these enzymes restored the dominant character of DR5-mediated apoptosis in 
both DLD-1 and HCT-116 cell lines (Zhang et al., 2019). Importantly fucosylation of DR5 has 
impact on ligand-independent receptor association resulting in better DISC formation. 
Basement for the use of DR5 specific ligands in treatment of colorectal cancer favours also the 
study pointing to the mRNA levels of different apoptosis involved genes: DR4, DR5, c-IAP1/2, 
XIAP and BIRC5/survivin genes in 100 colorectal cancer tissues from tumours from colorectal 
cancer patients. Analyses showed up-regulation of DR5, XIAP and BIRC5/survivin while c-
IAP1 and c-IAP2 were downregulated (Devetzi et al., 2016). CIAP1/2 is required for NFkB 
activation and likely negatively regulates necroptosis via ubiquitinilation of RIP1 kinase. 
Notably, among genes that we found upregulated in DR5-selective ligands treated cells were in 
addition to DR5 itself also cIAP1 and cIAP2. Interestingly, up-regulation of DR5 was observed 
independently on KRAS mutation status, while recent data showed involvement of DR5 in 
editing of tumour microenvironment and supporting the cancer progression in TRAIL apoptosis 
resistant KRAS mutated cancer cell lines (Karstedt et al., 2015; Karstedt et al., 2017). 
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     To broaden our study we included into our analysis of DR4/5-selective signalling pancreatic 
cancer cells. PANC-1 cell line showed similarly as HT-29 cells preferential signalling via DR5 
receptor. Both DR5-specific ligands and, notably, more efficient DR5.2 ligand were, despite 
lower cell surface expression of DR5 comparing to HT-29 cells, significantly more efficient in 
triggering apoptosis in PANC-1 cells. Notably, DR5.2 ligand triggered already significant 
apoptosis in PANC-1 cells even in the absence of a sensitizer/enhancer. Although the initial 
steps in TRAIL-induced apoptosis involving assembly of DISC and DISC mediated activation 
of caspase-8 proceeded similarly for the TST-TRAIL WT and all TRAIL receptors-specific 
variants in HT-29 cells, DR5-specific ligands are then superior in the amplification of apoptotic 
signalling. In contrast to our data, several reports mainly employing TRAIL receptor agonistic 
antibodies claim that pancreatic PANC-1 cancer cells preferentially use DR4 receptor for the 
induction of apoptosis (Lemke et al., 2010; Stadel et al., 2010). These apparent controversies 
could have several reasons likely including enhanced activity and stability of our TRAIL 
receptors-specific ligands. Enhanced efficacy of our ligands could be related to the trimerisation 
motif that allows forming of receptor trimers comparing to monoclonal antibodies. It was also 
published that post-translational modifications could have impact on DR signalling. For 
example positive impact on signalling was showed for O-glycosylation of DR5 or N-
glycosylation of DR4 thus our ligands might interact differently than other similar recombinant 
TRAIL receptor specific ligands with differently glycosylated cognate receptors in cancer cell 
specific manner (Wagner et al., 2007; Dufour et al., 2017). Very attractive reason for more 
effective kinetics in DR5 apoptotic signalling could be the result of more efficient chain 
formation of caspase-8 in DR5-selective DISC complexes with rapid kinetics of caspase-8 
processing (Dickens et al., 2012; Schleich et al., 2013). Additionally, screening of pancreatic 
and colorectal cancer cells for their response to TRAIL receptor-specific variants revealed the 
preference of DR5 receptor for PANC-1 cells (Mohr et al., 2015).  
     Other support of DR5 preference for apoptotic signalling in pancreatic cancer comes from 
the report documenting that pancreatic cancer stem cells from patient xenografts respond to 
DR5 agonistic antibody drozitumab (Eng et al., 2016). Treatment of immunocompromised 
SCID mice bearing patient-derived pancreatic tumour xenografts (PDX) with drozitumab alone 
inhibited growth of pancreatic cancer xenografts as well as inhibited development of tumours 
in mice implanted with pancreatic cancer stem cells (CSCs). Importantly drozitumab treatment 
was efficient even in the PDX with previously characterized (resistant) responses to 
Apo2L/TRAIL treatment. Additionally authors proved that nearly all pancreatic CSCs express 
DR5 and are responsive to drozitumab while only 25% of tumour mass express DR5. 
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Interestingly, though the majority of the bulk tumour did not express DR receptor, the 
continuous administration with drozitumab led to increase of DR5 expression and tumour 
regression. Moreover, the in vitro study with PANC-1 cell line showed that mRNA of DR5 
receptor increases with the time of drozitumab treatment, which is in an agreement with our 
data documenting increased DR5 mRNA expression in HT-29 cells treated with DR5-selective 
ligand. To sum up authors of this paper showed that targeting DR5 alone is sufficient to 
eliminate the population of pancreatic CSCs derived from patients as well as inhibit the further 
tumour growth of PDX in mice. The results from this study and importance of DR5 receptor in 
cancer stem cells are also strongly supported by in vitro experimental model mimicking breast 
cancer microenvironment of blood stream with circulating cancer cells which were found out 
to be resistant to TRAIL-induced apoptosis due to autophagy of DR5 receptor (Twomey et al., 
2019). Interestingly autophagy of not only DR5 but other death receptors including TNFR1, 
FasR and DR4 occurred but DR5 especially was targeted for lysosomal degradation.  
5.1.3 TRAIL-induced necroptosis 
     TRAIL can similarly as TNFR1 receptor induce other mode of regulated cell death, 
RIPK1/RIPK3 dependent necroptosis (Meurette et al., 2005; Jouan Lanhouet et al., 2012). One 
of the crucial players deciding whether the cell commits apoptosis or necroptosis is caspase-8. 
Caspase-8 mediated cleavage of RIPK1 and RIPK3 kinases, the core components of necrosome 
complex, blocks necroptosis and drives cells to apoptotic mode of cell death (Sosna et al., 
2016). Other key factors influencing necroptotic cell death are IAP proteins. These anti-
apoptotic E3 ubiquitin ligases target RIPK1 to proteosomal degradation (Sosna et al., 2016). 
Thus only combined treatment of HT-29 cells with pan-caspase inhibitor zVAD and IAP 
antagonist/Smac mimetic birinapant efficiently induced dose-dependent necroptosis in TRAIL 
WT-treated HT-29 cells. The efficient induction of necroptosis was proved by several 
approaches. At first pre-treatment of HT-29 cells with specific inhibitor of RIPK1, necrostatin-
1, and inhibitor of MLKL protein, necrosulfonamide, efficiently suppressed proceeding of cell 
death. Using pan-caspase inhibitor z-VAD prevented the activation and activity of caspase-8, 
displayed by decreased cleavage of the downstream apoptotic target of caspase-3, PARP 
protein. Moreover induction of necroptosis in HT-29 cells was also confirmed by 
phosphorylation of MLKL protein, which is together with RIPK1 and RIPK3 essential 
component of necrosome complex in death receptor-induced necroptosis (Voigt et al., 2014). 
However, in contrast to apoptosis, all DR4- and DR5-specific ligands were, at saturating 
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concentrations, equally effective in triggering RIP1- and MLKL-dependent necroptosis in HT-
29 cells. Notably, in spite of equal activation of necroptosis at saturating concentration of TST-
TRAIL ligands, we observed higher efficacy of the DR5.2 ligand at its lower concentration, 
likely reflecting its higher binding affinity for the DR5 receptor (Gasparian et al., 2009).  
5.1.4 NFκB, p38 and JNK kinase signalling 
     TRAIL-induced activation of DR4 or DR5 receptors in both permissive and resistant cancer 
cells leads in addition to cell death signalling also to the activation of non-canonical/auxiliary 
signalling pathways often enhancing cell survival or proliferation. Activation of these signalling 
pathways especially in cancer cells resistant to TRAIL-induced apoptosis would be 
counterproductive  and taking in account recent studies indicating metastasis-promoting 
activity of TRAIL, suppressing these auxiliary signalling would be essential for any 
consideration of TRAIL-based therapy in cancer treatment  (Karstedt et al., 2015; Hartwig et 
al., 2017). Activated TRAIL receptors DR4/5 depending on circumstances and cellular 
origin/background can activate following signalling: RIPK1, IκB/NFκB, MAPK p38, MAP3K 
TAK1, JNK1/2, ERK1/2, PKC, PI3K/Akt or Src (Karstedt et al., 2017). In our study we mainly 
focused on the activation of NFκB pathway, p38 and JNK kinases. TRAIL-mediated activation 
of NFκB signalling can attenuate TRAIL-induced apoptosis via transactivation of anti-
apoptotic proteins as cFLIP or Bcl-XL and in some cases could promote tumour cell migration 
and invasion without influencing the proliferation (Karstedt et al., 2015; Hartwig et al., 2017). 
Treatment of colorectal HT-29 as well as pancreatic PANC-1 cell lines with TRAIL ligands led 
to the efficient induction of NFκB signalling pathway, reflected mainly in the phosphorylation 
its inhibitor IκBa. In an agreement with apoptotic signalling, DR5-selective ligands were also 
most effective inducers of NFkB signalling. Interestingly, NFκB can in addition to its anti-
apoptotic transcriptome also mediate up-regulation of death receptors DR4 and DR5. We were 
interested whether dominant character of DR5 receptor could be reflected also in the 
transcription level of both receptors DR4 and DR5. Using WT ligand and ligands specific to 
DR4 and DR5 we observed that WT TRAIL induced higher expression of DR5 than DR4 
receptor. DR5 ligands, in consistence with previous data, induced increase of DR5 receptor 
expression and interestingly also 2-times folder increase in the expression of DR4 receptor. 
Surprisingly ligand specific to DR4 receptor did not induce higher expression of its own cognate 
receptor but induced 2-times fold enhancement of DR5 expression. The enhancement of DR5 
mRNA expression thus also reflects increased efficacy of DR5-selective ligands in the 
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activation of NFkB signalling suggesting that this signalling is in our cells likely responsible 
for the increased expression of DR5.  
     Similarly the activation of other non-canonical pathways, members of stress kinase 
subfamily of MAP kinases, p38 and JNK, was significantly stronger in cells treated with DR5-
specific ligands. p38 was shown to have anti-apoptotic as well as pro-apoptotic effect in TRAIL 
induced signalling. For example in prostate cancer cells led phosphorylation of p38 by induction 
of TRAIL signalling to up-regulation of anti-apoptotic protein Mcl-1 while in HeLa cell line 
was activating of p38 kinase substantial for proceeding of cell death (Azijli et al., 2013). JNK 
kinases can have either opposite effects on cell survival and depending on circumstances and 
cellular context might promote survival or enhance pro-apoptotic signalling. JNK kinase can 
synergistically contribute to TRAIL-induced apoptosis by phosphorylating Bim protein and 
thus facilitating mitochondrial apoptosis. Additionally JNKs activated by TRAIL receptors can 
phosphorylate the key component of autophagic pathway, Beclin-1, resulting in autophagy 
induced cell death in HCT116 cells (Azijli et al., 2013). We report that JNK kinase is 
predominantly induced by DR5 receptor in HT-29 and PANC-1 and this activation could have 
contributed to higher levels of measured cell death in apoptotic conditions in both cell lines. 
Therefore, very low activation of JNKs upon DR4.2 treatment of HT-29 cells could be an 
additional reason for poor performance of DR4.2 ligand in inducing apoptosis of these cells.  
     We were also interested, whether the necroptotic conditions would influence non-death 
auxiliary signalling induced by TRAIL ligands. Interestingly, upon necroptotic conditions 
TRAIL receptor-specific ligands enhanced activation these signalling pathways to a similar 
extent blunting differences between DR4- and DR5-triggered signalling. One of the reasons 
could be related to the endocytosis and endosomal acidification in a process of pro-death 
signalling from TRAIL receptors (Horova et al., 2013). Other reason could be that in apoptotic 
signalling, dynamin 1-mediated endocytosis likely attenuates TRAIL-mediated apoptosis, but 
it apparently does not affect TRAIL-triggered necroptosis (Zhang et al., 2008; Sosna et al., 
2016; Reis et al., 2017).  
     In conclusion, we showed, in correlation with the published data, that combination of several 
sensitizing compounds as homoharringtonine or ABT-737 efficiently induced apoptosis in 
TRAIL resistant colon cancer HT-29 and pancreatic cancer PANC-1 cells. We also showed 
efficient induction of necroptosis in HT-29 cells. Using a number of approaches, we proved 
that TRAIL receptor-specific pro-apoptotic signalling in colorectal and in pancreatic cancer 
cells does largely rely on DR5 death receptor and this dependence is blunted in TRAIL-
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triggered necroptosis. Importantly, we showed that in resistant HT-29 and PANC-1 cells were 
efficiently induced several kinase pathways which were predominantly relying signalling from 
activated DR5 receptor.  
 
5.2 Human embryonic and induced pluripotent stem cells express TRAIL 
receptors and can be sensitized to TRAIL-induced apoptosis 
     The potent capability of stem cells to reconstitute the damaged and aged tissues drove 
attention to the stem cell research and their application in regenerative medicine. Moreover 
cancer patients undergoing radiation and chemotherapy are exposed to many harmful agents 
causing depletion of tissue stem cells pool. Secondary processes, such as oxidative stress and 
inflammation that accompany the radiation therapy not only regulate regeneration of normal 
tissue but could have impact on cell survival of any engrafted or transplanted stem cells. It was 
shown that human embryonic and induced pluripotent stem cells were sensitive to several stress 
factors inducing DNA damage and undergo apoptosis even at low exposure. This apoptosis is 
driven through the activation of intrinsic mitochondrial pathway, but not much is known about 
the extrinsic, death receptors-mediated one. Our study with Vladimir Vinarsky and col. from 
Masaryk University in Brno revealed the first insight into expression profile and functional state 
of major death domain-containing receptors TNFR1, Fas/CD95 and especially TRAIL 
receptors DR4 and DR5 in hESC and hiPSC. We showed that expression of Fas receptor and 
TNFR1 was rather low or none comparing to TRAIL receptors DR4 and DR5. Therefore we 
focused in further experiments on characterizing of TRAIL-induced signalling in stem cells. 
We found that despite moderate protein expression and cell membrane localization of both pro-
apoptotic TRAIL receptors were both hESCs and hiPSCs resistant to TRAIL-induced 
apoptosis. hESCs treatment with inhibitor of translation homoharringtonine suppressed 
expression of two anti-apoptotic proteins Mcl-1 and cFLIP and led to their sensitization to 
TRAIL-induced apoptosis. This data are in agreement with the previous results from our lab, 
where we showed that using HHT efficiently led to lower protein level of Mcl-1 and cFLIP in 
colorectal carcinoma cell lines (Beranova et al., 2013). Experiments presented in this Thesis 
concerned the involvement of cFLIP in resistance to TRAIL-induced apoptosis in hESC and 
hiPSC. cFLIP protein is coded by CFLAR gene located on human chromosome 2q33-34 
adjacent to genes coding caspase-8 and -10. In contrast to caspase-8/10, cFLIP, which is highly 
similar to pro-caspase-8, does not possess a catalytically active domain. Three isoforms: FLIP-
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L, FLIP-S and FLIP-R act as inhibitors of caspase-8 activation by hetero-dimerizing with the 
molecules of pro-caspase-8 at DISC, only FLIP-L was shown to have an ability to activate 
caspase-8, although this activation has rather limited capacity to cleave the substrates. The 
proposed anti-apoptotic function of cFLIP and its important regulatory function in cell survival 
of hESC and hiPSC was confirmed by shRNA-mediated knock-down of cFLIP expression, 
which led to increased sensitization of these cells to TRAIL-induced apoptosis. The protecting 
role of cFLIP in human pluripotent stem cells was also suggested in hematopoietic stem cells 
showing that stem cell factors caused increase of cFLIP levels and inhibited FasL-mediated 
apoptosis of human erythroid progenitor cells (Chung et al., 2003). In addition, suppression of 
cFLIP expression in breast cancer stem cells resulted in selective TRAIL-mediated cell death 
of these cells (Piggott et al., 2015). Interestingly, cFLIP can in addition to apoptosis play some 
role in necroptosis, specific type of cell death proceeding under caspase compromised 
conditions and depending on the activity of RIPK1 kinase. Not much is known about 
necroptosis in stem cells, but few papers refer to necroptotic signalling to be responsible for the 
bone marrow failure in patients (Roderick et al., 2014). To exclude the possibility of 
contribution of necroptosis to the pool of dying cells, were cell lines with downregulated 
expression of cFLIP tested for the involvement of RIPK1 kinase. Our data indicate that cell 
death observed in hESC and hiPSC mediated by TRAIL ligand was caspase dependent and 
incubation of cells with inhibitor of RIPK1 necrostatin-1 did not modulate their survival in any 
way. To conclude, we showed that cFLIP protein plays an important regulatory signalling node 
in human stem cells hESC and hiPSC and contributes to their defence against potent death 
inducing factors. 
 
5.3 Streptomycetes metabolites of the Manumycin family differently 
sensitize colon cancer cells to TRAIL-induced apoptosis via enhanced 
production of reactive oxygen species (not published). 
     Manumycin A (Man A), Manumycin B (Man B) and Asukamycin (Asuc) are all 
Streptomyces secondary metabolites from the manumycin family. These compounds are known 
as inhibitors of farnesyl transferase (FTase), enzyme responsible for the post-translational 
modification of Ras protein family (Tuladhar et al., 2018). Blocking Ras farnesylation leads to 
retaining of Ras in the cytosol where this normally membrane associated protein cannot target 
its downstream interaction partners. Ras belongs to the most frequent mutated oncogenes in 
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human cancers and is involved in regulation of a number of important cellular processes. In our 
screening for the potent sensitizers of TRAIL-induced apoptosis in colorectal cancer cell lines, 
we revealed Man A as the only one capable to efficiently increase level of apoptosis comparing 
to Man B and Asuc. Man A was shown to have anti-tumour capability in several types of 
cancers (Cho et al., 2015; Zhang et al., 2016). This capability of Man A was mostly understood 
as the attribution of FTase to impair the activity of Ras, but recent studies and our results show 
that Man A can stimulate signalling pathways independently of the inhibitory function of FTase 
and the other possible regulatory mechanisms are involved (Cho et al., 2015; Zhang et al., 2016; 
Tuladhar et al., 2018). As we documented, Man A strongly enhanced apoptotic signalling in 
colorectal carcinoma RKO and SW-620 cells, triggered either by TRAIL ligand or by inhibitors 
of Bcl-2 and Bcl-Xl proteins, while the other metabolites, Man B and Asuc, were less effective 
or ineffective in this enhancement. These results point to participation of Man A in regulation 
of extrinsic as well as intrinsic apoptotic pathway. The extrinsic apoptotic pathway is in most 
cell lines insufficient to induce apoptosis by itself and the signal triggered from death receptors 
is amplified by engagement of mitochondria by caspase-8-cleaved tBid. We showed that Man 
A in combination with TRAIL ligand strongly enhances processing of tBid and subsequently 
downstream mitochondria activated caspases, thus supporting the role of Man A in extrinsic 
mediated cell death, underlined by stronger cleavage of caspase-8. The possible mechanism 
along the regulatory node at the DISC level was proposed from Juang Jae Cho and his 
colleagues, who published that ManA induced increase of DR4 and DR5 expression in dose 
dependent manner in oral squamosus cell carcinoma cells (Cho, Chae et al. 2015). They 
suggested that increase of TRAIL receptors is mediated through CHOP protein, which was 
shown to be involved in ER stress induced apoptosis (Yamaguchi and Wang 2004). Other 
regulatory node of the apoptotic pathway presents mitochondria mediated or intrinsic signalling 
regulated mainly by family of Bcl-2 proteins. Increased cell death induced by incubation of 
Man A with inhibitor of Bcl-2 anti-apoptotic protein (ABT-199) or Bcl-2/Bcl-Xl (ABT-737) 
revealed involvement of Man A in regulation of mitochondria induced apoptosis independently 
on ligand induced extrinsic apoptosis. To analyse the mechanism behind the regulation of 
intrinsic apoptotic signalling by Man A we subjected HT-29, RKO and SW-620 cells for the 
mitochondrial ROS production. Indeed, we found out that ManA but not Man B or Asuc largely 
enhanced production of mitochondrial ROS. Mitochondrial ROS were already proposed as very 
effective triggers of intrinsic apoptotic signalling and potent sensitizers of cancer cells to other 
pro-apoptotic agents such as TRAIL. For example vitamin E succinate and its mitochondria-
targeted analogue mitoVES inhibit electron transfer in mitochondrial complex II, which leads 
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to increased ROS production and potent sensitization of resistant mesotheliomal cells to 
TRAIL-induced apoptosis (Tomassetti et al., 2004). Thus similarly enhanced ROS production 
triggered by ManA might be behind its strong sensitizing effect to TRAIL and BH3 analogues 
triggered apoptosis (Zhang et al., 2016). However, the presumed mitochondrial target of ManA 
and mode of its mitochondrial uncoupling resulting in boost of ROS production is still 
unknown.  
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6 CONCLUSIONS 
 
1. I prepared several novel TRAIL receptor specific ligands, which can efficiently and 
selectively induce signalling through their cognate receptors DR4 or DR5. 
2. I showed that designing new recombinant TRAIL receptor agonists, specifically 
targeting DR4 or DR5, can lead to more effective induction of apoptosis in cancer cells 
comparing to wild type ligand. Thus receptor specific ligands could be used for a patient 
tailored therapy due to their ability of specific targeting the cognate TRAIL receptors 
dominantly signalling in different types of cancer.  
3. I also proved that DR4 and DR5 receptor are not equally regulated during apoptosis in 
colorectal HT-29 and pancreatic PANC-1 cells and the resulting cell response not only 
in apoptosis, but also in other auxiliary pathways could be affected by different events 
downstream from the receptor level. 
4. From my results is obvious that apoptosis and necroptosis could be induced by the same 
DR4 and DR5 receptors but the signalling from these two receptors is differently 
regulated during apoptotic and necroptotic conditions.  
5. In second part I showed that human embryonic and induced pluripotent stem cells 
express all components of TRAIL-induced apoptotic signalling and apoptosis in these 
cells is regulated by anti-apoptotic protein cFLIP. 
6. Finally in the last part, I showed that Manumycin-A is a potent sensitizer of TRAIL-
induced apoptosis in resistant colorectal cancer cell lines and this sensitizing effect 
might be at least partially achieved by increased production of mitochondrial ROS. 
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